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p97 is an essential ATPase associated with various cellular activities (AAA+) that functions as a 
segregase in diverse cellular processes, including the maintenance of proteostasis. p97 interacts 
with different cofactors that target it to distinct pathways; an important example is the 
deubiquitinase ataxin3, which collaborates with p97 in endoplasmic reticulum associated 
degradation. However, the molecular details of this interaction have been unclear. We have 
characterized the binding of ataxin3 to p97, showing that ataxin3 binds with low-micromolar 
affinity to both wild-type p97 and mutants linked to degenerative disorders known as multisystem 
proteinopathy 1 (MSP1); we further showed that the stoichiometry of binding is one ataxin3 
molecule per p97 hexamer. We have mapped the binding determinants on each protein, 
demonstrating that ataxin3’s p97/VCP-binding motif (VBM) interacts with the inter-lobe cleft in 
the N-domain of p97. We also probed the nucleotide dependence of this interaction, confirming 
that ataxin3 and p97 associate in the presence of ATP and in the absence of nucleotide, but not in 
the presence of ADP. Our experiments suggest that an ADP-driven downward movement of the 
p97 N-terminal domain dislodges ataxin3 by inducing a steric clash between the D1-domain and 
ataxin3’s C-terminus. In contrast, MSP1 mutants of p97 bind ataxin3 irrespective of their nucleotide 
state, indicating a failure by these mutants to translate ADP binding into a movement of the N-
terminal domain. Our model provides a mechanistic explanation for how nucleotides regulate the 





CHAPTER 1: Introduction 
 
1.1. Protein homeostasis: Maintaining the factory  
Protein homeostasis or proteostasis (1) is the synthesis, folding, transport and degradation 
of cellular proteins. The precise coordination of these processes sustains the fine balance of protein 
build-up and breakdown, which is vital to cell survival and function. Proteins are the worker 
molecules that perform almost every essential cellular activity, thus efficient protein turnover is 
key to a normal healthy cell. The proteostasis network is formed by a complex series of tightly 
regulated pathways that enforce protein quality control and ensure proteome stability (reviewed 
in (2)). The outcome is a steady supply of proteins, perfectly folded into their native conformations 
and targeted to appropriate locations in the cell. 
The native three-dimensional structure of the protein is critical for its proper function. 
Proteins are folded into their distinct structures co-translationally, as the nascent polypeptide 
chain emerges from the ribosome. The nature of protein folding and the cellular environment is 
such that misfolding and unfolding events are relatively common. 
The proteostasis systems exhibit a variety of strategies to degrade and clear away terminally 
misfolded proteins in a timely manner. When proteins misfold, specific pathways are activated, 
such as the cytosolic heat shock response and the unfolded protein response in the endoplasmic 
reticulum (ER) or mitochondria; these systems aid in refolding proteins via chaperones like the 
Hsp family (reviewed in (3,4)), or stimulate their clearance via the proteolytic machinery. Failure 
to refold, degrade or efficiently sequester aberrant proteins causes proteotoxic stress and 
ultimately leads to proteostatic collapse, which is deleterious to the cell (2). Potentially toxic 
proteins are allowed to accumulate and the cell suffers various protein aggregation-associated 
disorders that are typically neurodegenerative, such as Alzheimer’s, Parkinson’s, and 
Huntington’s diseases (5). Most of these manifest later in life and are strongly correlated with 
aging, since our body loses the ability to efficiently remove defective proteins with age.   
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1.1.1. Degradation pathways: Waste management 
The selective degradation of misfolded, damaged or aggregated proteins significantly 
contributes to maintaining a healthy proteome. Proteome stability can be perturbed by various 
physiological conditions, including metabolic or developmental changes in the cell or 
environmental stress (6). Eukaryotic cells respond to these challenges and ensure efficient protein 
turn-over by coordinating two major proteolytic pathways: the ubiquitin proteasome system 
(UPS), and a lysosomal degradation pathway termed autophagy (Fig. 1.1). 
 
 
Figure 1.1 Cellular degradation pathways. The UPS and the aggresome-autophagy system are 
the two major routes for protein degradation in the cell. After a protein is translated in the 
cytoplasm, or co-translated into the ER, it undergoes multiple folding cycles to achieve its native 
state. Proteins that cannot reach their native fold, that unfold during cellular stress, or have 
accomplished their function, must be eliminated. Small and short-lived proteins are degraded by 
the UPS, while larger proteins, and aggregates of misfolded proteins, are handled by the 
autophagy system. The UPS also eliminates substrates through ER-, mitochondrial-, and 
chromatin-associated degradation. Figure adapted from (6,7,9).    
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The UPS is the primary degradation route for small polypeptides and short-lived proteins 
(7). The substrate protein is marked for destruction by the covalent attachment of the small protein 
tag ubiquitin, which then targets it to the proteasome – a barrel-shaped proteinase, within which 
substrates are cleaved into peptides ~2-30 residues long (8). Larger protein substrates or 
aggregates that could obstruct the proteasome’s inner chamber are generally handled by the 
second proteolytic pathway, autophagy, a cellular degradation system that eliminates not only 
large protein aggregates, but also cytosolic components, organelles and pathogens via lysosomes 
(reviewed in (9-11)). In addition, the autophagy machinery recycles a large percent of old and 
worn-out proteins and is responsible for organelle turn-over. Both the UPS and autophagy 
pathways rely on crosstalk, and collaborate with each other to effectively degrade cellular proteins 
(9). 
 
1.1.2.  Ubiquitin proteasome system: Stamped for the shredder 
Approximately 80-90 % of cellular proteolysis is carried out by the UPS, though this may 
vary based on cell type and physiological state (12). The UPS comprises two distinct, successive 
steps: 1) tagging, whereby aberrant protein substrates are identified and specifically tagged by 
the covalent attachment of ubiquitin chains, and 2) degradation, where the tagged substrates 
are subsequently broken down by the proteasome (13,14) (Fig. 1.1). The proteasomal machinery 
is a multimeric ATP-dependent protease complex, the various components of which selectively 
recognize and break down ubiquitin-tagged substrates. Consequently, the ubiquitin tag induces 
substrate processing and functions as a degradation signal or a degron (12). 
Ubiquitin, a small 76-residue protein, is attached to the ε-amine of Lys side chains on the 
substrate via an isopeptide bond (Fig. 1.2A). Ubiquitin itself contains seven Lys residues, which 
can in turn be linked to additional ubiquitin molecules to form poly-ubiquitin chains. The 
covalent attachment of mono- and poly-ubiquitin (termed ubiquitination) is a common post-
translational modification. Ubiquitination controls not only degradation events in the cell, but 
also various non-proteolytic processes including protein interactions, enzyme activity, 
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trafficking and subcellular localization, as well as larger scale events like transcription, 
apoptosis and cell cycle regulation (15-17). The fate of the ubiquitin-tagged substrate is specified 
by the position of the ubiquitin modifier, the chain length and the type of chain linkage (18). 
For example, K11- and K48-linked poly-ubiquitin are	canonical signals for degradation, and 
specifically target substrates to the proteasome (13). 
 
 
Figure 1.2 Ubiquitination and deubiquitination reactions. A, shows the conjugation of 
ubiquitin (orange) onto a substrate (yellow) lysine side chain, via an isopeptide linkage. The 
reaction involves a sequential three-step enzyme cascade. Ubiquitin is first activated by E1 
(green), which enables it to bind E2 (blue), before it is finally transferred to the substrate by the 
E3 ligase (pink). B, shows the cleavage of ubiquitin molecules from chains, or from the substrate 
it is attached to, by a DUB (purple). The catalytic cysteine hydrolyses the covalent isopeptide 
bond between the lysine side chain and the C-terminal of ubiquitin. The site of cleavage is marked 
by the red bolt. Figure adapted from (14,18-20).   
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The UPS thus controls the fate of a large number of proteins and consequently demands a 
high degree of specificity of both the ubiquitin signal and the tagged substrate. Ubiquitination 
results from a sequential three-step enzyme cascade of increasing specificity (Fig. 1.2A). The 
ubiquitin molecule is first activated by an E1-activating enzyme, which enables it to bind to a 
ubiquitin-carrier protein E2, before it is finally transferred to the substrate by a ubiquitin ligase 
E3 (14). A minimum chain length of four ubiquitin molecules is required for the substrate to be 
recognized by the proteasomal machinery (13). The chain must then be trimmed or entirely 
cleaved prior to degradation, before the substrate can enter the proteasome. This is 
accomplished by peptidases referred to as deubiquitinating enzymes (DUBs) (19). DUBs reverse 
the ubiquitin signal attached to substrates by E1/E2/E3 enzymes (Fig. 1.2B). In the context of 
protein degradation, they also trim or tailor chains to achieve optimal ubiquitin-chain topology 
for substrate recycling or breakdown (19). On a larger scale, they regulate ubiquitin levels in the 
cell by processing ubiquitin precursors, recovering ubiquitin from small molecule adducts, and 
recycling ubiquitin chains from proteasome substrates (20). 
A large proportion of UPS substrates originate in the ER, and must be extracted into the 
cytosol to be degraded and recycled; this component of the UPS is termed ER-associated 
degradation (ERAD) (21).  
 
1.1.3. Endoplasmic reticulum associated degradation: Extractor machines 
Secretory and membrane proteins, as well as those of the endocytic system, enter the ER 
by co-translation, where they complete their folding cycles and acquire various post-
translational modifications. Subsequently, they are delivered to the appropriate organelle, 
embedded in the plasma membrane, or transported outside the cell to perform their function 
(21). During their folding process, some proteins fail to adopt a stable conformation. At times, 
more than half of the newly translated proteins may never reach maturity. The mechanisms that 
discriminate folded proteins from terminally misfolded proteins are unclear, and are currently 
thought to involve the ER-resident chaperones and co-chaperones (22). Even after multiple 
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folding cycles aided by chaperones, proteins that cannot be rescued must be extracted from the 
ER back into the cytosol, where they can be degraded and recycled by the proteasome as part 
of the UPS (Fig. 1.1). The ubiquitin tag on these substrates not only signals degradation, but is 
also required for their extraction from the ER (17,18).  
The ERAD pathway is thus a quality-control strategy aimed at restoring proteostasis 
during an unfolding crisis, wherein the ER cooperates tightly with the UPS to identify, tag, 
extract, and degrade aberrant and accumulated protein substrates. 
 
1.1.4. Autophagy: The junk yard 
Autophagy (“self-eating”) is the bulk degradative system that not only eliminates proteins, 
but also larger cellular constituents including whole organelles, cytosolic elements, parts of the 
ER, and intracellular pathogens (11). In this system, substrates are delivered to lysosomes, 
where they are degraded by lysosomal hydrolases. Autophagy can be categorized into three 
types based on how the substrate is delivered: chaperone-mediated autophagy, 
microautophagy, and macroautophagy (23). The last is usually referred to by the general term 
“autophagy” and is responsible for eliminating large protein aggregates (24) (Fig. 1.1). During 
autophagic degradation, substrates are sequestered by a unique organelle termed the 
autophagosome, which forms as a double-layered membrane structure. Fusion of this organelle 
with late endosomal compartments creates amphisomes, which subsequently fuse with the 
lysosome for digestion by acidic hydrolases (23). 
Autophagy and the UPS were initially believed to be independent of each other in modes 
of action, core machinery and substrate specificity. However, recent studies suggest that cells 
function on a single proteostasis network, wherein both pathways coordinate with each other 
and share numerous components (reviewed in (9,12,25)). For example, autophagy is activated 
when the UPS is impaired or when the proteasome is inhibited (26-29), which is indicative of a 
compensatory mechanism. The ubiquitination process is central to both pathways, as ubiquitin-
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tagged proteins are also eliminated via autophagy (12). Interestingly, autophagy can even 
degrade proteasomes in response to starvation and damage ((30), and reviewed in (31)). 
Our studies revolve around two major players of the degradation pathways. One of them 
is the molecular motor p97, a key regulator of the UPS that extracts substrates from membranes 
and aggregates, and is also essential for autophagosome maturation (32). The other is the DUB 
ataxin3, thought to be a sentinel directing the degradation pathways. Ataxin3’s DUB activity 
helps target substrates to the proteasome, and also contributes to the clearance of proteins by 
autophagy and aggresome formation (33-36). The two proteins directly interact with each other, 
and function in concert to maintain proteostasis (37,38). The research described in this 
dissertation is of a biochemical nature, focused on the molecular mechanism of the p97-ataxin3 
interaction, and ataxin3 enzyme activity. 
 
1.2. The AAA+ ATPase p97 
The protein p97, also known as valosin-containing protein or VCP in mammals, cdc48 in 
yeast and plants, CDC-48 in worms, and Ter94 in flies, is an essential ATPase associated with 
various cellular activities (AAA+ superfamily). The presence of two highly conserved AAA 
domains within the protein classifies it as a Type II AAA+ ATPase (reviewed in (32)). Members of 
this large, functionally diverse family generally exist as double-ringed oligomers (p97 forms a 
hexamer), and often function as molecular motors, harnessing the energy of ATP hydrolysis to 
perform mechanical work in species from bacteria to humans. Other proteins in this group include 
the N-ethylmaleimide-sensitive fusion protein (NSF) that functions in vesicular transport 
processes (reviewed in (39)), the nuclear VCP-like protein (NVL) that functions in ribosome 
biogenesis (reviewed in (40), and the PEX1 and PEX6 proteins involved in peroxisome biogenesis 
(reviewed in (41)). Unlike various other AAA+ proteins, p97 does not depend on the presence of 
nucleotides for its hexameric assembly. 
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1.2.1. Structural assembly 
The structure of p97 has been extensively studied for over a decade, by various techniques 
including X-ray crystallography (42), cryo-electron microscopy (cryo-EM) (43), nuclear magnetic 
resonance (NMR) (44) and small-angle x-ray scattering (SAXS) (45). Initially, negatively-stained 
EM samples provided basic information about the ring-like hexameric shape of the molecule 
(46,47). Subsequent structural efforts were limited to medium resolution (3.5–4.7 Å) images of full-
length p97, with higher resolution structures of isolated domains that were indispensable in 
determining the architectural details of the molecule (48,49). Recently, in a study by Banerjee et al. 
(43), the latest advancements in cryo-EM technology were used to obtain near-atomic resolution 
structures of native, full-length p97 hexamers in multiple conformational states, and in the 
presence and absence of exogenous nucleotides.  
 
1.2.1.1. Overall architecture 
Fig. 1.3A depicts the domain organization of a single p97 protomer. Each protomer has a 
predicted molecular weight of ~90 kDa. The native, full-length p97 complex assembles as a 
homohexamer, with each protomer comprising an N-terminal domain (denoted hereafter as the 
N-domain), two tandem AAA ATPase domains termed D1 and D2, and a short, unstructured C-
terminal tail (Fig. 1.3A). Within each protomer, the three domains are connected by short linkers 
termed N-D1 and D1-D2 loops, which lack secondary structure. The D1- and D2- domains form 
two coaxially-stacked hexameric rings, with an average diameter of ~130 Å. In comparison, the 
D2-ring appears larger and more conformationally dynamic than the D1-ring (43). The rings 
surround a central pore ~20 Å wide and ~70 Å in length, lined with substrate-interacting loops. 
The arrangement of the N-domains around the outer periphery of the D1-ring, together with the 





Figure 1.3 Structure of p97. A, is the schematic domain organization of a single p97 protomer 
that comprises an N-terminal domain (green), D1- and D2-ATPase domains (cyan and deep blue 
respectively), two linker regions, and an unstructured C-terminal region. The scale below each 
domain shows the length in amino acids. B, is the structure of full-length hexameric p97 (PDB 
entry 5FTK (43) in the ADP-bound form), as viewed down the 6-fold symmetry axis from the top 
(above), and when rotated by 90° to generate the side view (below). The top view is presented 
with the approximate diameters of the D1-ring and the central pore, while the side view is 
annotated with width and height measurements. The N-domain is colored green, and the D1- 
and D2-domains are cyan and deep blue, respectively. C, shows a single N-domain with the Nn 
and Nc lobes, connected by a flexible linker. The upper view is rotated 90° clockwise around the 
in-plane horizontal axis to obtain the view below. The surface representation clearly shows the 
large inter-lobe cleft, which is a major binding pocket for numerous p97 cofactors. 
  
 10 
1.2.1.2. The N-domain  
The N-domain (residues 1 – 186) has a globular, bi-lobed structure, comprised of two sub-
domains, Nn at its N-terminal and Nc at its C-terminal, connected by a flexible linker of ~6 
residues. Nn has a double Ψ β-barrel structure, with six β strands forming the barrel’s sides and 
two Ψ crossover loops. Nc has an α+β structure, with a central β-sheet of four antiparallel strands 
(Fig. 1.3C). A large cleft, lined with hydrophobic residues, is formed between the Nn and Nc lobes, 
and serves as a major binding pocket for a multitude of p97 cofactors (50) (see section 1.2.2). The 
N-domain is also involved in p97-substrate interactions (51). 
 
1.2.1.3. The D1- and D2- domains 
The D1 (residues 209-462) and D2 (residues 481-763) domains are aligned along a vertical 
axis in a head-to-tail manner within each protomer, and share a similar overall structure. 
Approximately 250 residues from each domain contribute to the AAA cassette that bears the 
active site for ATP hydrolysis. Thus, both rings have inherent ATPase activity, however D1 is less 
active than D2 (52). The AAA cassettes contain two sub-domains each: a larger N-terminal RecA-
like α/β-fold domain that mediates hexameric ring formation and contains the active site, and a 
smaller C-terminal α-helical bundle domain (32). The six active sites are located at the interfaces 
between the adjacent protomers and are formed by Walker A and B motifs, responsible for 
nucleotide binding and hydrolysis respectively (52), along with an arginine-finger motif. 
The classical Walker A motif (GxxxGKT, x is any residue) includes a β-strand followed by a 
glycine-rich loop, ending in an α-helix. A highly-conserved lysine in the loop (Lys251 in D1, and 
Lys524 in D2 (Fig. 1.4)) senses the state of the bound nucleotide by interacting with the terminal 
phosphate group. The loop is thus referred to as the “P loop”. Mutagenesis of this critical lysine 
in either domain severely perturbs nucleotide binding (52). The Walker B motif (hhhhDE, h for 
hydrophobic residue) includes an aspartate that coordinates the Mg2+ ion, and a glutamate that is 
essential for ATPase activity (53) (Fig. 1.4). The arginine-finger residue (Arg359 in D1 and Arg635 
in D2) projects into the active site, stabilizes the nucleotide’s leaving γ–phosphate group and 
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stimulates ATP hydrolysis. Notably, this residue is contributed by the adjacent protomer in the 




Figure 1.4 Structure of the AAA cassettes in p97 D1- and D2-domains. A, shows the D1-
domain, and B, shows the D2-domain of a p97 protomer bound to ATPγS (PDB entry 5FTN (43)). 
The AAA cassette comprises a RecA-like domain (orange) and a characteristic helical domain 
(cyan). An ATPγS, bound at the interface between the two domains, is shown in purple in D1, and 
red in D2, and the Mg2+ ion is shown in light pink. The Walker A motif or P-loop is depicted in 
yellow, with the conserved lysine residue shown in stick representation and labelled. The Walker 
B motif is shown in green, and the two conserved acidic residues, aspartate and glutamate, are 
represented by stick models and labelled. The nucleotide-binding site communicates with the 
adjacent protomer via the arginine finger motif (grey), which contacts the bound nucleotide. 
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1.2.1.4. The C-terminal tail 
Unlike other AAA+ members, p97 has an unstructured, highly flexible C-terminal tail 
(residues 764-806) that extends beyond its D2-domain. This region is involved in regulating the 
molecule’s ATPase activity; C-terminal truncation mutants display reduced activity (54). The tail 
also contains phosphorylation sites that modulate the binding of a subset of p97 cofactors, as well 
as the protein’s subcellular localization and hexamer stability (50,54).  
 
1.2.2. p97 cofactors 
Over thirty p97-interacting proteins have been identified by proteomic studies and 
biochemical assays, and this number is expected to increase. Just last year, in 2016, a yeast two-
hybrid screen by Arumughan et al. (55) detected eight new cofactors for human p97. Typically, 
they are multi-domain proteins containing p97-binding modules along with domains that either 
promote interaction with other proteins, or possess enzyme activity.  
Despite the abundance of cofactors, they can be categorized into a few distinct groups based 
on their conserved p97-binding modules. The vast majority interacts with p97’s N-domain, either 
via domain motifs like the ubiquitin regulatory X (UBX) domain or the UBX-like (UBL) domain, 
or via linear peptide motifs including the VCP/p97-interacting motif (VIM), VCP/p97-binding 
motif (VBM), and the SHP-binding motif. Despite considerable differences in their structures, the 
p97-binding modules recognize and bind in or near the same inter-lobe cleft of the N-domain. A 
smaller subset of cofactors recognizes the unstructured C-terminal tail, and binds via 
PNGase/UBA or UBX (PUB) or PLAP, Ufd3p and Lup1p (PUL) domains (reviewed in (50)). 
Cofactors partner with p97 in different ways. Much of the binding mechanism is dictated by 
the stoichiometry and spatial arrangement of the complex. The hexameric structure potentially 
offers six identical binding sites for each cofactor around the ring. Typically, only one or a few of 
these are occupied by a single cofactor, which leaves room for others to bind. While some cofactors 
bind simultaneously to different protomers, others exhibit mutually exclusive binding, and some 
display a hierarchy in their binding patterns (reviewed in (32,50)).  
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Through these cofactor interactions, the N-domain couples mechanochemical ATPase 
activity to the unfolding or disassembly of p97 substrates. Cofactors may be roughly classified 
into substrate-recruiters that direct p97 to specific pathways, and substrate-processors, typically 
enzymes that fine-tune function within a given pathway. Diverse functions of p97-cofactor 
complexes, and their ability to recruit additional proteins, stem from differing symmetries and 
stoichiometries of these complexes (56-58).  
 
 
Figure 1.5 Nucleotide-induced conformational changes. A, shows three distinct conformations 
of p97 bound to various nucleotides (PDB entries 5FTN, 5FTM and 5FTK (43)). The nucleotide 
states of the D1 and D2 are mentioned below each structure. Alternate protomers are colored 
green and blue, and the bound nucleotide is colored pink for ATPγS, or purple for ADP. The grey 
arrows demonstrate the movements of the N- and D2-domains during the transition from the 
previous conformation. B, shows ribbon representations of the side view of a p97 protomer in the 
down (left) and up (right) conformations (PDB entries 5FTK and 5FTN (43)), with the N-, D1-, and 
D2- domains shown in green, cyan, and deep blue respectively, and the two linkers in red. The 
grey dashed lines represent the plane of the D1-ring. C, shows the side view of a p97 protomer, 
with both the up (light green) and down (deep green) conformations of the N-domain. Comparison 
of N-domain residues in the two conformations shows that the central D150 undergoes a hinged 
upward displacement of ~12 Å, sweeping an angle of ~17° (measured from G408), while a far edge 
residue P178 translates ~42 Å. The inset is a cartoon representation showing the N-domain 
displacement, and the location of the residues used for measurements. 
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1.2.3. Nucleotide-induced conformational changes 
p97 undergoes dramatic intra- and inter-protomer conformational changes during its 
ATPase cycle, and the mechanical force generated is directed towards remodeling substrate 
molecules. Early attempts to study these changes by cryo-EM were limited by low resolutions of 
20–30 Å, but provided evidence of moderate rotational movements attributed to the opening and 
closing of the central pore (48). In addition to limiting resolutions, the six ATPase domains within 
each ring are not synchronized during ATP hydrolysis, which adds to the challenges in studying 
p97 conformational dynamics. Recent advances in high-resolution cryo-EM have led to the 
detection of at least three well-defined, distinct conformations of p97 bound to various nucleotides 
(Fig. 1.5A) (43). Conformational changes involve large corkscrew-like rotational twists in D2, 
coupled with significant “up-down” movements of the N-domain relative to the D1-ring. N-
domain movements are largely induced by the nucleotide bound in D1; ATP or ATPγS favors the 
“up” position, and ADP induces a “down” position (where the N-domains are coplanar to the D1-
ring) (Fig. 1.5B). Comparison of the up and down structures in (43) reveals that the relative center 
of the N-domain (measured at D150) undergoes a hinged upward displacement of ~12 Å, 
sweeping an angle of ~17° (measured from G408), while a far edge residue on the N-domain (P178) 
translates a distance of ~42 Å (Fig. 1.5C). 
These up-down conformational shifts have also been verified by SAXS analysis (59). In 
contrast, all crystal structures of p97 to date, with and without nucleotide analogs, reflect the ADP-
bound down-state and reveal only minor structural changes (42,49,60). Perhaps crystal packing 
constraints limited the detection of functionally relevant conformational states. However, Tang et 
al. (59) recently crystallized a mutant form of the p97 hexamer (see section 2.5), with ATPγS bound 
in the D1 and all six N-domains in the up-state.  
p97 exhibits complex and dynamic structural transformations. At any given time, the D1 and 
D2 within each of the six protomers can exist in different nucleotide-bound states, supporting the 
observation that these domains do not work in a concerted manner. In addition, ADP is often 
prebound to the D1, with typically 0.9 ADP molecules per p97 monomer (52). This may account 
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for the heterogeneity in the positions of the six N-domains observed in some cryo-EM experiments 
(43). Moreover, the six protomers around the ring also communicate with each other in a system 
termed the intersubunit signaling network (ISS) (50). The ISS couples the conformation of the 
central substrate-translocating pore to the nucleotide state of the same protomer, which is then 
transmitted to the adjacent protomer and thereby coordinates ATP hydrolysis in trans (61). The 
ISS is also involved in interprotomer motion transmission – the vertical transmitting of signals 
from the D2 to the D1, via the D1-D2 linker (62).  
 
1.2.3.1. Conformational changes influence cofactor binding 
It makes perfect sense that nucleotide-induced conformational changes, specifically those 
associated with D1, influence the binding of N-domain cofactors and may thus regulate the 
physiological functions of p97. Nevertheless, we lack mechanistic insight into such 
conformational control. These effects may have thus far escaped detection because most structural 
studies, with and without cofactors, are conducted with isolated N-domains (44,58,63-65). In both 
up- and down- states, the cofactor-binding cleft is available but orients differently. Since cofactors 
vary in shapes and sizes, it is highly conceivable that some of their binding will be obstructed by 
spatial restrictions in different N-domain states. 
It is however clear that p97’s nucleotide state determines the binding of some cofactors; for 
example, p47 exhibits an 8-fold decrease in affinity for ADP-bound p97 compared to its ATP-
bound form (66). Conversely, cofactor-binding may provoke conformational changes and regulate 
ATP hydrolysis, as observed for p37 – the first known p97-activating cofactor to trigger a 11-fold 
enhancement of its catalytic efficiency (67).  
 
1.2.3.2. Conformational changes influence ATPase activity 
N-domain flexibility is crucial for p97’s catalytic activity. The orientations of the N-domain 
and D1D2 linker, relative to the D1-ring, are directly correlated to ATP hydrolysis. The flexible 
form of the protein is competent for activity, while forms of the protein that are locked in the 
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coplanar or down conformations are inactive (54). N-domain movements could thereby induce 
transitions from an active to an inactive form as part of the hydrolysis cycle, and these transitions 
would generate the force required to remodel substrates and regular cofactor interactions as part 
of p97’s cellular functions.  
 
1.2.4. Biological functions of p97 
ATP hydrolysis in the D1 and D2 is harnessed to perform mechanical work, allowing p97 to 
function as a segregase in processes as varied as cell-cycle regulation, transcriptional activation, 
DNA-damage repair, and membrane fusion (68). The protein’s general mode of action is to extract 
polypeptides from large protein assemblies and aggregates, or from cellular structures like 
membranes and chromatin. p97’s diverse functions have been extensively reviewed elsewhere 
(68-71), and can be broadly summarized into three categories.  
The first, and one of p97’s most significant cellular roles, is to maintain proteostasis (68), 
wherein the protein contributes to both proteasomal degradation and autophagy. In this context, 
its most widely studied function is in the ERAD pathway. Through specific interactions with 
various membrane-associated cofactors, p97 is recruited to the ER membrane, where it captures 
and extracts misfolded polypeptides. The protein can also release membrane-bound transcription 
factors, and extract polypeptides from the mitochondrial outer membrane to facilitate 
mitochondria-associated degradation (32). In addition to its segregase function, p97 also shuttles 
polypeptides to the proteasome. p97 function is also implicated in autophagy, as it assists in 
autophagosome biogenesis and maturation (72,73). 
Secondly, p97 exhibits chromatin-associated functions as it releases proteins from chromatin 
in a manner analogous to ERAD and thus assists in chromatin-associated degradation (74).  
Thirdly, biochemical and genetic evidence implicates p97 function in membrane fusion 
events and vesicular trafficking (75,76). In its capacity as a molecular motor, the protein facilitates 
the fusion of vesicles at the end of mitosis that leads to the formation of the golgi apparatus (77).   
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1.2.5. p97 MSP1 mutations and related disorders 
As would be expected for a key component of regulatory and degradation pathways, p97 
dysfunction is associated with numerous degenerative diseases. Missense mutations in p97 cause 
a set of heterogeneous disorders collectively termed Multisystem Proteinopathy Type 1 (MSP1), 
which include inclusion body myopathy, Paget disease of the bone and frontotemporal dementia 
(IBMPFD), and amyotrophic lateral sclerosis (78). Moreover, p97 dysfunction directly correlates 
to failures in proteostasis, and is also associated with a wider spectrum of diseases like familial 
Parkinsonism, Lewy body disease and Huntington disease (79). 
 
1.2.6. Disease pathology 
MSP1 is an autosomal-dominant, progressive and ultimately fatal disorder affecting brain, 
muscle and bone tissue. Despite embryonic lethality in p97 knock-out mice (80) and accelerated 
MSP1 pathology in homozygote p97 mutant mice (81), the pathogenic mutations are well tolerated 
and affect only a subset of p97 functions. Moreover, developmental abnormalities are not 
observed in affected individuals. This is consistent with MSP1 being a late-onset disease, and 
clinical pathology clearly indicates a defect in maintaining proteostasis. Pathological features of 
MSP1 in patient samples involve rimmed vacuoles in muscle tissue and nuclear inclusions in 
neurons, both which stain positive for p97 and ubiquitin (82-84). This suggests that defects in p97-
mediated protein quality control networks may contribute to disease etiology.  
 
1.2.7. Structural and functional alterations 
To date, over 30 MSP1-related mutations in 17 different residues within p97 have been 
identified. Typically, they are located at the interface between the N- and D1- domains and within 
the ND1 linker, neither of which overlap with any nucleotide-binding sites or cofactor-binding 
pockets (67) (Fig. 2.9). This suggests that the primary basis of dysfunction in mutant p97 is faulty 
communication between N- and D1- domains. The effects of MSP1 mutations are evident in 1) 
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disrupted cellular functions, 2) altered nucleotide-binding and hydrolysis, 3) altered 
conformational changes, and 4) imbalanced cofactor association (reviewed in (85)). 
 
1.2.7.1. Disrupted cellular functions 
MSP1 mutations have been linked to defects in multiple proteostasis degradation pathways 
including the UPS, autophagy (72), and endosome-lysosomal fusion (75). A pathological hallmark 
of MSP is the co-localization of mutant p97 with ubiquitinated-protein inclusions, directly 
indicative of a defective UPS (82,83). Mutants also disrupt autophagosome and endosome 
maturation, leading to vacuolation, weakness and muscle atrophy (86,87). In addition, ubiquitin 
is often co-localized in vacuoles with other proteins like TDP-43, a substrate for both proteasomal 
and autophagic degradation (88). The long term degenerative effects of these mutants on brain, 
bone and muscle tissues are yet another indication of disrupted proteostasis, and lead to the 
progressive failure of different systems in the body. 
 
1.2.7.2. Altered nucleotide binding and hydrolysis 
None of the MSP1 mutations have been found in nucleotide-binding pockets, but 
interestingly, they still affect nucleotide-binding in the D1. ITC experiments have revealed a 2- to 
5- fold decrease in the ADP binding affinity of mutant D1 compared to wild-type, which facilitates 
better access to other nucleotides for these mutants (59,66). Decreased prebound ADP has also 
been observed in ND1 fragments harboring R155H and R95G mutations (59). Furthermore, none 
of the mutations seem to abolish p97 ATPase activity. With a few exceptions that do not alter 
activity (53,89), the general effect of most MSP1-associated mutations is to significantly increase 
ATP hydrolysis (54,90,91). 
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1.2.7.3. Altered conformational changes 
The structure of the MSP1-associated R155H mutant, with ADP in the D1, is very similar to 
wild-type p97 with all N-domains in the down state (59). However, crystal structures of two 
common mutants with ATPγS in the D1 show all six N-domains in the up conformation, which 
has been correlated with decreased ADP binding to D1 (59). This suggests that mutations do not 
alter p97’s overall structure, but instead disrupt the up-down equilibrium of the N-domains 
(59,92). The disrupted conformational equilibrium is attributed to defective inter-domain 
communication within MSP1 mutants. Mutant D1 is less likely to be occupied by ADP to begin 
with, and when ADP does bind, the mutants are unable to effectively transduce the ADP-bound 
signal from the D1 to the N-domains. Consequently, mutant N-domains seldom adopt the down 
state, and this has implications in both, the function of p97, and its interaction with cofactors.  
 
1.2.7.4. Imbalanced cofactor association 
None of the identified MSP1 mutations are at p97-cofactor binding interfaces, so their effects 
on cofactor association are most likely indirect and subtle. Consequently, cofactor-binding 
experiments, comparing wild-type p97 to mutants, must be interpreted with caution. Studies 
using purified proteins are often inconsistent with cell-based experiments, and do not recapitulate 
the differences in cofactor-binding ability observed between wild-type p97 and MSP1 variants. 
For example, mutant p97 precipitates more Ufd1/Npl4 than wild-type in cultured cells, but not in 
vitro using pull-down assays (53,89,91). Such discrepancies in cofactor binding may be resolved 
by accounting for p97’s nucleotide state (see section 1.2.7.2). Despite the challenges in detecting 
subtle differences, studies of p97 mutants have demonstrated altered interactions with various 
cofactors from the endocytic pathway, as well as with UPS components. Unlike wild-type p97, the 
R155H mutant does not form a complex with CAV1-Ubxd1 (75). Additionally, R95G and R155H 
mutants also bind less of the ubiquitin ligase E4B and significantly elevated amounts of ataxin3, 
when compared to the wild-type. This has been observed in cultured cells, as well as under 
pathophysiological conditions, in primary myoblasts from MSP1 patients (53).   
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1.3. The DUB ataxin3 
DUBs are dynamic enzymes that hydrolyze the covalent isopeptide bonds between ubiquitin 
and a target protein, as well as between ubiquitin molecules in a chain (Fig. 1.2B). They reverse 
the ubiquitin signal in a manner analogous to the reversal of the kinase signal on target molecules 
by phosphatases (reviewed in (93-95)). However, the diverse assemblage of ubiquitin 
modifications on targets within a cell necessitates a certain level of specificity in DUB activity. 
Some DUBs may exhibit differential activity towards certain ubiquitin linkages, while some may 
display a size or substrate preference for the target protein conjugated to the ubiquitin C-terminal 
(96). Substrate specificity, as well as inherent DUB activity, is often regulated through their 
interactions with various binding-partners (97). Individual DUBs assemble into distinct protein 
complexes, or may even be part of large ubiquitin ligase complexes, in order to function as 
dynamic regulators of the UPS (19). 
The human Josephin proteins form one the five major families of DUBs, and ataxin3 is the 
founding member and most widely studied of these enzymes. The other members of this family 
include the ataxin3-like protein (AT3L), Josephin-1, and Josephin-2, all of which exhibit DUB 
activity by means of a highly conserved Josephin domain that serves as the catalytic center (34,98). 
However, all four proteins vastly differ in their catalytic efficiencies and substrate specificities 
(99). 
Ataxin3 has been implicated in various ubiquitin-dependent protein quality-control 
pathways, both in its capacity as a DUB (33,34,100), and in its ability to recognize and bind 
polyubiquitin chains (101,102). In its normal form, it facilitates the degradation of substrates 
targeted for destruction. However, a mutant form of the protein that possesses an expanded 
polyglutamine (polyQ) tract of pathological length aggregates and causes the neurodegenerative 
disorder spinocerebellar ataxia type-3 (SCA3) or Machado-Joseph disease (103-107). Thus, ataxin3 
both supports normal protein clearance, and in its mutant form disrupts the same process.   
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1.3.1. Structural organization 
Ataxin3 is composed of around 364 amino acids and has a molecular weight of 42 kDa. At 
its N terminus is the Josephin domain (residues 1–180 in humans; designated Josephin after 
Machado-Joseph disease), a globular cysteine protease module that possesses DUB activity, and 
is highly conserved from yeast to humans (100). Downstream of the Josephin is a relatively 
conserved region that contains two contiguous ubiquitin-interacting motifs (UIMs), followed by 
a loosely structured C-terminal tail (Fig. 2.1). The polyQ repeat region of variable length is located 
within the C terminus; the tract comprises 11–40 glutamine repeats in normal individuals, and is 
typically expanded to 55–85 repeats in disease states (reviewed in (103,108,109)). The C-terminal 
tail may also contain an atypical third UIM as a consequence of alternate splicing events, which 
give rise to multiple protein isoforms or splice variants (34,110). 
Ataxin3 associates with ubiquitin and ubiquitinated substrates primarily through its UIMs 
(111), which exhibit cooperative binding and a preference for tetra-ubiquitin and longer chains 
(34). Besides these motifs, two additional distinct ubiquitin-binding sites are present within the 
Josephin domain (Fig. 3.1). One is the active site, and the other overlaps with a site that recognizes 
the UBL domain of Rad23B, a proteasomal shuttling factor (102). The Josephin can thus bind two 
mono-ubiquitin molecules with low affinity and no apparent cooperativity (102). Consequently, 
the UIMs and Josephin synergistically modulate ataxin3’s DUB activity and substrate specificity. 
Other specific motifs in the Josephin domain and the C-terminal region facilitate binding to 
chromatin, transcriptional regulation, and protein-protein interactions (reviewed in more detail 
in (112-114)). 
 
1.3.2. Ataxin3 chain-trimming activity 
Ataxin3 DUB activity maps to the conserved Josephin domain that hosts the enzymatic cleft 
(Fig 3.1). The catalytic triad formed by C14, H119 and N134 demonstrates a close similarity in 
secondary structure and organization to the active site in papain-like cysteine proteases, including 
those of the ubiquitin C-terminal hydrolases (UCH) and ubiquitin-specific proteases (USP) 
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families (115). Ataxin3 indeed functions as a cysteine protease, albeit less efficiently than other 
ubiquitin proteases like USP7 and UCHL3 (98). Mutation of the crucial C14 residue abolishes its 
catalytic activity; this mutant is useful in studying loss-of-function effects (34,100).  
The isolated Josephin domain exhibits the same DUB activity as full-length ataxin3 (34,36,98), 
and the protein is an endo-type DUB (116). It cleaves polyubiquitin chains of five or more subunits 
to produce tetra-ubiquitin, with a preference for K63- and mixed-linkage long chains (117,118). In 
fact, K48- and K63-linked di-ubiquitin are found to be extremely poor substrates (118). Ataxin3 
thus functions as a “molecular ruler” of sorts. The UIMs play a significant role in this form of 
chain specificity by restricting the types of substrates that are hydrolyzed by the Josephin. Their 
influence is further illustrated by mutation of the UIMs, which enhances the cleavage of K48-
linked substrates (117). The Josephin and UIMs thus cooperate to trim polyubiquitin chains down 
to an optimal length for proteasomal delivery. In vivo studies are consistent with these in vitro 
observations (117), and confirm ataxin3’s preference for high molecular weight mixed-linkage 
chains; presumably the DUB prevents the accumulation of very large, aberrantly structured 
ubiquitin chains in the cell, through its chain-trimming activities.  
Interestingly, ataxin3 is also mono- or oligo-ubiquitinated (primarily at Lys-117 in the 
Josephin domain) in a UIM-dependent manner in vivo (119), which enhances its DUB activity 
without altering its preference for K63-linked chains (120). This form of regulation explains why 
ataxin3 exhibits low catalytic efficiency in vitro, but is relatively more active in cells. 
Ubiquitination of endogenous ataxin3 is enhanced during times of cellular stress, when the 
proteasome is inhibited, during the unfolded protein response or when excess ubiquitin is present 
(103). These observations suggest that ataxin3’s cellular functions in protein quality control and 
clearance are modulated via ubiquitination of the DUB itself. 
 
1.3.3. Cellular functions of ataxin3 
Ataxin3 is deeply involved in the clearance of misfolded, toxic and aggregated proteins, and 
forms a critical component of both major degradation systems, the UPS as well as aggregation-
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autophagy pathways (33,34). The DUB was initially reported to 1) bind polyubiquitin chains of 
four or more moieties with high affinity via its UIMs (33), and 2) preferentially hydrolyze K63-
linked chains, branched chains and mixed linkages (117); this correlates with the minimal length 
and chain type required for the proteasomal delivery of substrates (121). The synergistic action of 
the Josephin with the UIMs selects for substrates that are heavily or improperly ubiquitinated, 
and protects chains from being overly trimmed. There is also evidence that closely links ataxin3 
to the ERAD pathway, in its capacity as a DUB (38). As reported in (38) and (37), the protein 
interacts with the p97 extractor complex, trims ubiquitin chains to their optimal topology, and 
facilitates the shuttling of ubiquitinated substrates to Rad23 (via association with its UBL (122)), 
or directly to the proteasome (through interaction with the 19S and 20S subunits (33)). In addition, 
ataxin3 restricts ubiquitin chains on ERAD substrates by modulating E3 ligase activity. For 
example, it deubiquitinates and terminates the activity of the E3 ligase CHIP when the ubiquitin 
chain on its substrate reaches a critical length (123).  
Ataxin3 DUB activity is also required to maintain the pool of free ubiquitin in the cell for 
normal proteostasis. In fact, proteostatic defects are observed in mice with a mutant ataxin3 allele 
or worms lacking ataxin3, evident as an enhanced stress response in these animals (124,125). 
Interestingly, ataxin3 knockout worms also exhibit an inhibited clearance of p97 substrates (126), 
which links the two proteins in a model system. On the other hand, the abnormal overexpression 
of wild-type ataxin3 leads to the accumulation of ERAD substrates like TCRα and CD3δ (33,37,38), 
reminiscent of dominant negative inhibition observed in other ERAD proteins (127-129). Thus, 
ataxin3 DUB activity is fine-tuned and tightly regulated to facilitate the flux of proteins through 
the UPS. 
Ataxin3 function has also been observed in other cellular contexts. The DUB can serve as a 
transcriptional regulator to promote or inhibit the expression of target genes (112,114,130,131), 
such as those that encode molecular chaperones. Studies in mice and worms demonstrate that 
ataxin3 is largely responsible for maintaining basal levels of chaperones at a steady state in vivo 
(125,126,132). Ataxin3-deficient fibroblasts have reduced levels of basal and stress-induced Hsp70 
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and its regulator Hsf1, and the loss of ataxin3 in knockout mice primarily affects Hsp70 
transcription, rather than chaperone turnover (132).  
Ataxin3 also binds dynein, the microtubule-based motor protein (36), and may serve as an 
adaptor that links polyubiquitinated substrates to dynein motor complexes, thereby facilitating 
retrograde transport of substrates to aggresomes. In vitro assays also indicate a direct interaction 
between ataxin3 and HDAC6 (133), and the two proteins are found co-localized with aggresomes 
and pre-aggresome particles (134). Moreover, ataxin3 DUB activity and ubiquitin binding are both 
critical for aggresome development, since neither the isolated Josephin nor UIM-deficient mutants 
can rescue the decreased aggresome formation observed in ataxin3 depleted cells (36). Such 
observations, along with other studies (35,133-135) clearly indicate a role for ataxin3 in the 
aggresome-autophagy pathway. 
Autophagy is an important degradation pathway for large assemblies of aggregated, 
misfolded proteins, in situations where the UPS and chaperone systems have failed. This pathway 
is especially involved in the clearance of polyQ expanded, aggregation-prone proteins like 
huntingtin, forms of tau and alpha-synuclein, and interestingly the mutant form of ataxin3. The 
DUB, therefore, not only participates in aggresome formation, but its pathological expanded form 
misfolds, aggregates and serves as a substrate to be cleared by autophagy (136-138). This portrays 
ataxin3 as a “Jekyll-and-Hyde” protein, which in its normal form suppresses neurodegeneration 
and cytotoxicity from polyQ disease proteins via its DUB activity, but in its expanded mutant 
form disrupts protein clearance pathways.  
 
1.3.4. PolyQ-expanded ataxin3: Disease and dysfunction 
Ataxin3 is encoded by the gene responsible for SCA3 (also termed Machado-Joseph disease), 
an autosomal-dominant neurodegenerative disorder that is caused by an anomalous expansion 
of the polymorphic polyQ tract, located at ataxin3’s C terminus (103,108,109). As a rare, hereditary 
disorder, SCA3 is characterized by a pathologically expanded number of CAG trinucleotide 
repeats at the transcript level, which codes for polyQ (139), and is likely formed by slippage 
 25 
during DNA replication. The result is a toxic form of ataxin3, which is prone to misfolding and 
aggregation. The expanded polyQ may impair protein clearance via one or a combination of the 
following ways: 1) misfolded ataxin3 forms toxic oligomers and blocks its own recognition and 
degradation by the proteasome, 2) the expanded polyQ alters ataxin3’s native activity and 
interactions in p97-mediated protein degradation (loss-of-function mutant), causing a functional 
disruption of the UPS and ERAD and proteotoxic stress, 3) cleavage of ataxin3 produces unstable, 
toxic fragments containing the polyQ tract, and 4) the aberrant interaction of mutant ataxin3 with 
specific transcription factors causes errors in transcription (gain-of-function mutant) (103). In any 
case, mutant ataxin3 interferes with cellular quality-control pathways and is the main cause of 
neurodegeneration. As discussed above, wild-type ataxin3 behaves in an opposite manner by 
promoting protein clearance and is neuroprotective. This pattern has been extensively verified in 
a fruit fly model by overexpression experiments. Native ataxin3 clearly suppresses 
neurodegeneration in a DUB-dependent manner, and pathogenic ataxin3 with 50–78Q repeats 
induces neurodegeneration (135,140-142). However, ataxin3 was not found to suppress 
neurodegeneration in an analogous manner in mammalian models (143). 
 
1.4. Significance of the p97-ataxin3 interaction 
1.4.1. Regulation of the ERAD pathway 
The ER is a major site of protein synthesis, folding and assembly in eukaryotic cells. The 
ERAD pathway serves as the primary quality-control system that eliminates misfolded, 
aggregated or toxic proteins (21), and thus preserves ER proteostasis. The pathway is formed by 
a series of steps that export aberrant substrates out of the ER for degradation by the UPS (144), 
however, the exact sequence of events is unclear. It is known that the targeted substrates are 
deglycosylated, ubiquitinated, and finally extracted into the cytosol to be broken down by the 
proteasome (21,145), and that for each of these steps, various proteins and protein complexes are 
recruited and assembled around the target substrate. 
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Aberrant substrates are first targeted to their site of extraction at the ER membrane, 
presumably by ER resident chaperones (146). A subset of these substrates associates with the 
Derlins, a class of highly conserved membrane proteins that are thought to form a channel in the 
membrane (147-149). Other components of the ERAD complex are also recruited to these focal 
points in the membrane. p97 is recruited to the ER membrane by its association with integral 
membrane proteins including Derlin-1/2, SEL1L/Ubx2, and VCP-interacting membrane protein 
(VIMP) (147,150-153). These proteins also recruit the Hrd1p/Hrd3p E3 ligases that ubiquitinate 
the substrate (150,154). The assembly of the retrotranslocation complex, containing both the motor 
elements and the ubiquitination machinery, tightly couples substrate ubiquitination to extraction. 
Ubiquitination is thought to occur on the cytosolic side of the ER membrane, after a portion 
of the substrate emerges from the channel. In this way, the ubiquitin signal that is essential for 
extraction (144,155), can be recognized and processed by p97 and its cofactors, and may even 
activate the ATPase’s function. p97 forms a subcomplex with the Ufd1/Npl4 heterodimer; since 
both p97 and Ufd1 can bind ubiquitin (156), they then synergistically interact with and extract the 
ubiquitinated substrate (156-158). 
Both extraction and proteolysis in ERAD are dependent on the ubiquitin machinery; these 
are the enzymes that conjugate ubiquitin onto, and detach ubiquitin from substrates. The 
ubiquitin chain not only recruits p97, but also targets proteins to the proteasome. However, the 
chain must be trimmed or removed before the substrate can enter either the extraction or 
degradation apparatus (159). The cleavage is carried out by DUBs like ataxin3.  
Ataxin3 acts in conjunction with p97 to regulate the flux of proteins through ERAD (37,38). 
The DUB is thought to trim ubiquitin chains on ERAD substrates, and may even form a part of 
the retrotranslocation complex. The two proteins interact directly, both in cells (37,38,53,113,160), 
and when expressed recombinantly in vitro (38,113,160-162), and have been observed together in 
various multi-protein complexes at the ER membrane (38). Inhibiting ataxin3’s DUB activity 
compromises p97-mediated protein degradation (37,38). In addition, when ataxin3 is 
overexpressed in cells, it reduces p97’s association with Ufd1 and polyubiquitin, and inhibits the 
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extraction and degradation of substrates, possibly through a dominant negative effect (37). This 
suggests that unregulated binding between p97 and ataxin3 could alter the physiological 
regulation of the ERAD, especially in the context of disease-related mutants for either protein, and 
could thus contribute to disease pathogenesis. Indeed, p97 MSP 1 mutants precipitate significantly 
increased amounts of ataxin3 in HEK293T cells, and under physiological conditions, in myoblasts 
from MSP 1 patients (53). 
The precise function of ataxin3 has not been characterized, but its chain trimming activity is 
thought to influence p97-dependent extraction in several ways. The DUB may trim the 
polyubiquitin chain on a substrate to a specific length required to A) activate p97, or B) enter the 
central pore of p97 for extraction (163). C) Modulation of the chain by ataxin3 may facilitate 
recognition and transfer of the substrate from the ER membrane-bound ligase to the p97-
extraction complex (164). D) After substrates have been extracted into the cytosol and 
appropriately re-ubiquitinated, ataxin3 may aid in their transport to the proteasome. The DUB 
could either release them to a ubiquitin receptor like the Bag6 holdase complex, or a shuttling 
factor like Rad23 (33), or directly transport them to the proteasome (165). Ataxin3 may also edit 
the polyubiquitin chain on these substrates to maintain the appropriate degradation signal (159). 
 
1.4.2. Role in longevity and DNA repair pathways 
p97 and ataxin3 also collaborate in cellular processes other than ERAD. Briefly, their 
synergistic functioning regulates longevity and aging in worms, via the insulin – insulin-like 
growth factor-1 (IGF-1) signaling pathway. Ataxin3 cooperates with p97 to mediate the 
ubiquitination status of substrates within this pathway, and its DUB activity is essential for both, 
the stress response and for normal lifespan (126).  
The two proteins have also been implicated in DNA repair pathways. They function 
together, along with other processivity factors like the E4 ligase Ufd-2, within ubiquitination hubs 
that form after homologous recombination has been initiated at double-stranded break sites (166). 
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PolyQ expanded ataxin3 impairs the accumulation of p97 and its association with other DNA 
repair proteins, leading to defective p97 function and an increase in unrepaired breaks (167). 
A majority of these studies are at their initial stages, and reflect recent findings on alternate 
roles for the p97-ataxin3 interaction. Much remains to be elucidated about their concerted biology, 
both within and outside the ERAD pathway. 
The work presented in this dissertation, aims to advance the understanding of the p97-
ataxin3 interaction into more mechanistic and molecular realms. By employing complementary 
biophysical and biochemical techniques, we established an interaction model that may prove 
applicable to other p97 cofactors and has potential consequences for protein quality-control 
pathways. In addition, we have provided new insights into the regulation of ataxin3 DUB activity. 
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CHAPTER 2: Nucleotide-induced Conformation Changes  
Regulate the p97-Ataxin3 Interaction 
The work described in this chapter has been published in (168). 
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The protein p97, also known as valosin-containing protein or VCP, is an essential ATPase 
associated with various cellular activities (type II AAA+ family) (169). p97 forms a hexamer, with 
each protomer comprising an N-terminal domain, D1- and D2- ATPase domains, and an 
unstructured C-terminal region (Fig. 2.1A). The D1- and D2-domains form two coaxially-stacked 
rings, with the N-domains arranged around the periphery of the D1 ring (42,43).  
 
 
Figure. 2.1. Schematic representation of p97 and ataxin3. A, Structure of p97. At left is shown 
the domain organization of the p97 protomer. Each protomer comprises an N-terminal domain 
shown in light gray, D1- and D2- ATPase domains shown in dark gray and black respectively, and 
an unstructured C-terminal region. At right is shown a cartoon of the assembled hexamer, using 
the same shading. The D1- and D2- domains form two coaxially-stacked rings around a central 
pore, with the N-domains arranged along the periphery of the D1 ring. B, Domain organization of 
ataxin3 showing the Josephin domain, two ubiquitin-interacting motifs (UIMs), the p97/VCP-
binding motif (VBM), and the polyglutamine (polyQ) repeat region. The linkers, UIMs, VBM, and 
polyQ regions are not drawn to scale. The scales above each domain representation show length 
in amino acids.   
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ATP hydrolysis in the D1- and D2-domains is harnessed to perform mechanical work, allowing 
p97 to function as a segregase in processes as varied as cell-cycle regulation, transcriptional 
activation, DNA-damage repair, and membrane fusion (32,71). One of p97’s most significant 
cellular roles is to assist in maintaining proteostasis, and the protein contributes to both 
proteasomal degradation and autophagy (9,68,170-172). As would be expected for a key 
component of regulatory and degradation pathways, p97 dysfunction is associated with 
numerous degenerative disorders (78,79). Missense mutations in p97 cause a set of heterogeneous 
disorders collectively termed Multisystem Proteinopathy Type 1 (MSP1), which include inclusion 
body myopathy, Paget disease of the bone and frontotemporal dementia (IBMPFD), and 
amyotrophic lateral sclerosis (82,173,174). In cell culture, inhibiting or knocking down p97 induces 
endoplasmic reticulum (ER) stress, and triggers the unfolded protein response, with a 
concomitant buildup of poly-ubiquitinated substrates (175-180). p97 protects against the toxic 
effects of aggregation-prone proteins and localizes to cytosolic aggregates (113,181,182). It extracts 
misfolded and toxic substrates from such aggregates, as well as from macromolecular complexes 
and cellular membranes, in quality-control processes associated with chromatin and 
mitochondria (183-186) (reviewed in (145,187)). 
p97’s involvement in diverse cellular processes is coordinated by a multitude of cofactors 
that regulate its activity. These cofactors are roughly categorized into substrate-recruiters, which 
direct p97 to specific pathways, and substrate-processors, which are typically enzymes that fine-
tune p97 function (188). The assembly of p97-cofactor complexes drives the subcellular 
localization of p97, its specificity for substrates, and the ultimate fate of these substrates (189). An 
important substrate-processing cofactor is ataxin3, a member of the Machado-Joseph disease class 
of deubiquitinating enzymes (DUBs) (103). Ataxin3 is intimately involved in the clearance of 
misfolded proteins, playing significant roles in the ubiquitin-proteasome system (33,34,38) and 
the aggregation-autophagy system (35,136,137,190). Through its ubiquitin-related activities, it 
suppresses neurodegeneration and cytotoxicity from various polyglutamine-disease proteins 
(135,140,142). In particular, ataxin3 collaborates with p97 in the process of ER-associated 
degradation (ERAD) (164), in which proteins that are misfolded or otherwise marked for 
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destruction are removed from the ER and targeted to proteasomes. In addition, ataxin3 and p97 
cooperate outside ERAD in other processes involving protein degradation, such as the control of 
protein levels involved in the DNA damage response (166). In general, ataxin3 seems to facilitate 
degradation of proteins targeted for destruction. For example, ataxin3-knockout animals feature 
increased levels of poly-ubiquitinated proteins and increased levels of the stress response 
(124,125,191). Interestingly, a mutant form of ataxin3 containing an expanded polyglutamine tract 
gives rise to aggregates of misfolded protein, and causes the neurodegenerative disorder 
spinocerebellar ataxia type-3 (SCA3, also known as Machado-Joseph disease; (104-107,192,193)). 
Therefore, it appears that ataxin3 can both support normal protein degradation, and (in its mutant 
form) disrupt this same process. 
The p97-ataxin3 interaction was first observed via immunoprecipitation from cell extracts 
(33,113,194). Subsequent studies revealed that p97 and ataxin3 are found together in multi-protein 
ERAD complexes at the ER membrane and that the proteins also interact in vitro 
(37,38,113,193,194). Overexpression of a catalytically-inactive form of ataxin3 strongly inhibits the 
processing of ERAD substrates, while overexpression of the wild-type enzyme has a less 
pronounced, but still inhibitory effect, possibly due to a dominant-negative effect (37,38). The 
functionality of this interaction has been demonstrated in worms, where p97 and ataxin3 operate 
synergistically to promote degradation of key substrates (126). The p97-ataxin3 interaction is 
perturbed by mutations in p97 associated with MSP-1, as significantly elevated amounts of 
ataxin3 are associated with the mutant p97, as compared to wild-type protein (53). 
The molecular details of how p97 interacts with cofactors such as ataxin3 are only now being 
elucidated. It is becoming clear that different cofactors assemble into complexes with differing 
stoichiometries (57,58,195). It is also apparent that cofactor binding is influenced by major 
conformational changes within p97, which are driven by nucleotide binding and hydrolysis 
(43,54,61). Most p97 cofactors interact with the protein’s N-domain (196), which is significant 
because the N-domain can undergo significant “up-down” motions relative to the D1 ring (43). 
These conformational changes are largely induced by the nucleotide bound in the D1-domain, 
with ATP favoring the “up” position, while ADP induces a “down” position. The up-down 
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equilibrium is disrupted in MSP1 mutants (59,197), in which all six N-domains preferentially 
adopt the up-state, regardless of the nucleotide present; this behavior correlates with decreased 
ADP binding to the D1-domain in these mutants (66,67). Even though the MSP1 mutations affect 
nucleotide binding, they are not located at nucleotide-binding sites, nor at cofactor-binding 
interfaces. Instead, they are mostly found in the N-domain, with some occurring in the D1-domain 
and the N-D1 linker (79), suggesting that they might affect cofactor binding by perturbing the N-
domain conformation and/or inter-domain communication. 
In order to understand the precise interplay between ataxin3, p97, and p97’s ATPase cycle, a 
detailed analysis of binding is required. In this study, we characterized the p97-ataxin3 interaction 
for wild-type p97 and three common MSP1 mutants, localizing the determinants of binding for 
each partner and revealing that the dependence of binding upon nucleotide state is starkly 
different for the wild-type and mutant p97 proteins. We suggest a model in which ataxin3 binding 
is controlled by a nucleotide-induced shift of the N-domain conformation, which leads to steric 
displacement of ataxin3 in the ADP-bound state. This model has potential consequences for 
protein quality-control pathways in both normal and disease states, and may prove applicable to 
other p97 cofactors. 
 
2.2. Experimental Procedures 
2.2.1. Reagents 
Enzymes for cloning were purchased from New England Biolabs (Ipswich, MA). PCR 
primers were purchased from Integrated DNA Technologies Inc. (Coralville, IA) and sequencing 
of constructs was performed by Genewiz (South Plainfield, NJ). All chemicals were from Sigma-
Aldrich (St. Louis, MO) unless otherwise stated, and media components were purchased from 
Fisher Scientific. Chromatography columns were obtained from GE Healthcare, and all surface 
plasmon resonance sensor chips and chemicals were purchased from BioRad (Hercules, CA). The 
Rho1D4 monoclonal antibody was obtained from the University of British Columbia (Vancouver, 
Canada), and the 5nm Ni-NTA-Nanogold® was purchased from Nanoprobes Inc. (Yaphank, NY).   
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2.2.2. Cloning and Mutagenesis 
Human p97 and ataxin3 proteins were cloned into the pETHSUL vector (198), to generate N-
terminal hexahistidine (His6)-tagged SUMO fusion constructs, under T7 promoter control. p97 
was amplified by PCR from cDNA (Open Biosystems; clone ID 6502535). Ataxin3 was amplified 
from clones kindly provided by Randall Pittman and Henry Paulson; our ataxin3 sequence 
corresponds to that given in Kawaguchi et al. (107), except that the 26-residue polyglutamine tract 
corresponding to residues 292-317 was replaced by eleven glutamines. Constructs produced using 
the pETHSUL vector included one extra glycine at the N-terminus (not included in the numbering 
scheme). The following constructs were used in this work: full-length p97 (amino acids (aa) 1-
806), p97 N-domain (aa 1-187), p97ND1 (aa 1-480), full-length ataxin3 (aa 1-345), ataxin3 Josephin 
domain (aa 1-190), ataxin3 Josephin + UIMs (aa 1-263), ataxin3DC (aa 1-292), and ataxin3DN (aa 
220-345). The pProEX-HTb vector (Invitrogen, Carlsbad, CA) was also used to generate a full-
length, N-terminally His6-tagged ataxin3 construct (aa 1-361). The ataxin3 mutant 282ANAA285 and 
all p97 mutants (Y143A, L72A, R53A, G54W, K251A, K524A, K251A/K524A, R155C/N387C, 
R155H, L198W, A232E, L198W/R155C/N387C, A232E/R155C/N387C) were generated by one-step 
PCR-mediated site-directed mutagenesis (199). The C-terminal 1D4 epitope was introduced into 
the full-length p97 pETHSUL construct by one-step insertion mutagenesis (199). The C-terminal 
His6-tagged full-length p97 was cloned as a SUMO-p97 fusion insert into the pETCH vector (198), 
by Xba1/Xma1 digestion and ligation. Primer sequences and additional details are provided in 
Appendix 2 Supplemental Data section. Cloning, mutagenesis, and plasmid amplification were 
performed using the Escherichia coli Mach1 strain (Invitrogen). The human gp78 peptide 
(622VTLRRRMLAAAAERRLQKQ640) was purchased from Biomatik (Wilmington, DE). 
 
2.2.3. Protein Expression and Purification 
Detailed information about the preparation of various proteins is given in Appendix 2 
Supplemental Protocols. Briefly, all proteins were expressed in E. coli Rosetta (DE3) cells 
(Novagen), by induction with 1 mM isopropyl-b-D-thiogalactopyranoside at an A600 of 0.5–0.8, 
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followed by overnight incubation at 24 °C. Proteins were then purified by subtractive metal 
affinity chromatography on a HiTrap IMAC HP column (198), followed by size-exclusion 
chromatography (SEC) on a HiPrep Sephacryl S-300 HR column. The ataxin3 constructs required 
an additional anion-exchange chromatography step using a HiTrap Sepharose Q HP column. All 
proteins were concentrated to 8–10 mg/ml using an Amicon® stirred cell (Merck Millipore), 
shock-frozen in liquid nitrogen, and stored at –80°C. 
 
2.2.4. Surface Plasmon Resonance (SPR) 
All SPR experiments were performed on a BioRad ProteOn XPR36 at 25°C using ProteOn 
GLC sensor chips, unless otherwise stated. The full-length p97 hexamer was captured on the chip 
in an oriented manner, by employing the Rho1D4 epitope–antibody system (200,201). The Rho1D4 
monoclonal antibody was first immobilized to a density of ~3,500 Response Units (RU) on the chip 
using amine coupling, by injecting 0.1–0.5 mg/ml of the antibody for 7 min, using PBS (Alfa Aesar, 
Haverhill, MA), pH 7.4 and 0.005% Tweenâ 20 (VWR, Radnor, PA) as the running buffer. 1D4-
tagged full-length wild-type p97 and mutants were captured as ligands, to densities of 100–150 
RU, on the antibody-coated surfaces. Various concentrations of analytes, including ataxin3 and 
ataxin3 fragments with and without nucleotides, were passed over the chip at 150 µl/min, for the 
maximum possible contact time of 163 s. All interaction experiments were performed in a running 
buffer containing 25 mM Tris, pH 8.0, 200 mM KCl, 5 mM MgCl2, 0.1 mM tris(2-
carboxyethyl)phosphine (TCEP) (Gold Biotechnology Inc., Olivette, MO), 0.005% Tweenâ 20. 
Some experiments involving the p97 R155C/N387C variant included 7 mM DTT instead of TCEP, 
as indicated in the text. The surface was regenerated completely with three injections of freshly 
prepared 10 mM NaOH and 1% N-octyl-β-D-glucopyranoside (Anatrace, Maumee, OH), at 100 
µl/min for 18 s, before the next round of 1D4-tagged ligand capture. Additionally, full-length 
ataxin3 was used as an analyte for the p97 N-domain, which was directly immobilized on the 
sensor chip by amine coupling (500 RU), and for the His6-tagged full-length p97 hexamer, which 
was captured on a ProteOn HTG sensor chip (200–300 RU) (Appendix 2 supplemental Fig. S1). 
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Sensorgrams were processed and double referenced and the data were fit to an equilibrium 
binding model using GraphPad Prism 7.0 to derive the binding affinity. Detailed information on 
all SPR experiments and data analyses are available in the Appendix 2 Supplemental Protocols.  
 
2.2.5. Isothermal Titration Calorimetry (ITC) 
ITC measurements were conducted at 25 °C on a Nano ITC calorimeter (TA Instruments). 
Proteins were extensively dialyzed against 20 mM sodium phosphate, pH 7.0, 200 mM KCl, 5 mM 
b-mercaptoethanol (bME), and degassed for 15 min before each experiment. Full-length ataxin3, 
ataxin3DC, or ataxin3DN (400–855 µM) were placed in the syringe, and titrated as ligands into the 
sample cell containing 45 µM full-length p97 or 60–80 µM p97 N-domain. The first technical 
injection of 0.4 µl was followed by 25 injections of 2 µl into the sample cell (300 µl), using 250 rpm 
stirring and a 200 s delay between successive injections. At least three titration experiments were 
performed for each ligand, and the data were corrected for heats of dilution by injecting the same 
ligand concentration into a matched buffer. Corrected data were analyzed with a one-site binding 
model and nonlinear least-squares fitting to derive the KD, using the NanoAnalyze 3.5.0 software 
package. 
 
2.2.6. In Vitro Binding Assay 
For competition pull-down assays, His6-tagged ataxin3 was immobilized on Ni Sepharose 
Fast Flow beads (GE Healthcare) by mixing 50 µl of a 50% slurry with 100 µl of His6-ataxin3 (5 
mg/ml), for 5 min at room temperature (RT), and washing off unbound protein. The beads were 
then incubated at RT for 5 min with 80 µM p97ND1 or p97ND1 pre-incubated with 800 µM of the 
competing gp78 peptide (4 °C for 20 min + RT for 5 min). Ni Sepharose Fast Flow beads alone 
were used as a control. All assays were performed in 50 mM Tris, pH 8.0, 250 mM KCl, 5% glycerol, 
5 mM MgCl2 and 5 mM bME. The beads were centrifuged at 5,000 × g for 30 s in a 0.2 µm Nanosepâ 
MF centrifugal filter (ODM02C34; PALL Laboratory) and additionally washed four times with 
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400 µl of buffer. Bound proteins were eluted in 100 µl buffer containing 300 mM imidazole after a 
5 min incubation at RT, and analyzed by 12% (v/v) SDS-PAGE.  
 
2.2.7. ATPase Assays 
The ATPase activities of wild-type and mutant p97 proteins (Appendix 2 supplemental Figs. 
S6A, S7, and S8) were measured spectrophotometrically using an NADH-coupled system (202). 
The decrease in absorbance at 340 nm associated with oxidation of NADH was measured at 0.5 
min intervals over 40 min on a DU800 spectrophotometer (Beckman Coulter). The rate of ATP 
hydrolysis was calculated from the change in A340/min. The assay was performed at RT, in 
standard buffer (25 mM Tris, pH 8.0, 200 mM KCl, 5 mM MgCl2), containing 2 mM ATP, 3 mM 
phosphoenolpyruvate, pyruvate kinase (20 units/ml), lactate dehydrogenase (20 units/ml), 
NADH (200 µg/ml), and 5 µM protein, in a final volume of 85 µl. 
 
2.2.8. Electron Microscopy (EM) 
The complex of full-length ataxin3 + p97 was prepared by incubating 5 µM of purified p97 
hexamer (~3 mg/ml) with an 11-fold molar excess of ataxin3 at 4 °C for 15 min. The complex was 
further purified by SEC on a HiPrep Sephacryl S-300 HR column in 25 mM Tris, pH 8.0, 200 mM 
KCl, 5 mM MgCl2, 0.5 mM DTT (Appendix 2 supplemental Figs. S3B and S4). The fraction 
corresponding to the complex peak was diluted 20-fold (final concentration ~25 µg/ml) to achieve 
sufficient dispersion of individual particles and applied to freshly glow-discharged 400 square 
mesh copper EM grids (Electron Microscopy Sciences, Hatfield, PA), coated with Formvar/carbon 
film. The grids were stained with 2% uranyl acetate and excess liquid was blotted away with filter 
paper. Micrographs were collected on a FEI Tecnai T12 (120 kV, LaB6 filament) microscope, 
equipped with a Gatan UltraScan1000 CCD camera (2k × 2k pixels), using an indicated 
magnification of 52,000×, a defocus range between −0.7 to −1.5 µm, and an electron dose of 20 
e−/Å2. A total of 20,256 particles were selected with the EMAN Boxer (203). Two-dimensional (2D) 
classification generated in the RELION software (204,205) resulted in 50 class-average images. 
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For the chemical crosslinking, a mixture of 5 µM p97 hexamer and 55 µM His6-tagged ataxin3 
was incubated with EM-grade glutaraldehyde (0.05% final concentration) at 4 °C for 10 min, in 20 
mM HEPES, pH 8.0, 150 mM KCl, 2.5 mM MgCl2. The N-terminally His6-tagged ataxin3 construct 
was used because the VBM is near ataxin3’s C-terminus (see Fig. 2.4). The crosslinking reaction 
was terminated with Tris, pH 8.0 (25 mM final concentration). Unbound p97 was then removed 
by immobilized metal-affinity chromatography, which retained the His6-ataxin3-p97 complex. 
After elution, unbound His6-ataxin3 was removed by centrifugation at 5,000 × g for 15 min using 
a 100-kDa-cutoff Amicon® Ultra-15 centrifugal filter (Merck Millipore). After a final round of gel 
filtration as described above, the complex fraction was diluted 25-fold (final concentration ~10 
µg/ml), loaded onto grids, and stained with pH-neutralized 1% uranyl formate. 7,171 images were 
collected and processed as above, to give 50 class-average images. 
For the Nanogold-labelling, the His6-ataxin3-p97 complex (prepared as described above) was 
incubated with a five-fold molar excess of 5 nm-diameter Ni-NTA-Nanogold particles at 4 °C for 
10 min. Excess Nanogold was removed by centrifugation at 3,000 × g for 15 min using a 10-kDa-
cutoff Amicon® Ultra-0.5 centrifugal filter (Merck Millipore). The mixture was further purified 
by gel filtration using a Yarra SEC-3000 column (Phenomenex, Torrance, CA), in 25 mM Tris, pH 
7.5, 200 mM KCl, 5 mM MgCl2, 0.5 mM DTT, and the complex fraction was directly applied to grids 
(~3 µg/ml), stained with 2% uranyl formate, and imaged. See Appendix 2 supplemental Fig. S3B 
for sample preparation workflow and SEC chromatograms for all EM experiments. 
 
2.3. Results 
2.3.1. p97 interaction with ataxin3 
It has previously been demonstrated that GST-fused ataxin3 can pull down p97 from cell 
lysates, as well as from a solution of purified p97 (37,113). To quantitatively characterize this 
interaction, we used SPR, focusing first on the interaction between the full-length proteins. A C-
terminal 1D4 epitope (201) was used to immobilize the p97 hexamer in an oriented manner on a 
 38 
sensor chip. Ataxin3 was found to bind with an equilibrium dissociation constant (KD) of 3.7 ± 0.9 
µM (Fig. 2.2A). 
 
 
Figure 2.2. p97 interacts directly with ataxin3. A and B, Ataxin3 binding to p97 as measured 
by SPR. A, full-length ataxin3 binding to full-length p97 or B, full-length ataxin3 binding to the 
p97 N-domain. The upper panels show normalized equilibrium binding responses, fit to a one-
site binding model; the lower panels show representative sensorgrams. The dashed lines 
represent the response range used to determine the equilibrium fit (for both A and B, n ≥ 3 for 
each concentration). C and D, Ataxin3 binding to p97 as measured by ITC; C, full-length p97 or 
D, the p97 N-domain. The upper panels show the raw data for injection of full-length ataxin3 into 
a cell containing either full-length p97 or the p97 N-domain, and the bottom panels show the 
integrated heat data as a function of the p97/ataxin3 mole ratio (closed circles). The solid lines 
represent the best fit of a one-site model to the data.   
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A similar KD value (2.2 ± 0.2 µM) was derived using a different type of sensor chip and 
immobilization chemistry, indicating that the binding observed is not tag-specific (see Appendix 
2 supplemental Fig. S1, A and B). Since most p97 cofactors interact with the protein’s N-terminal 
domain, we next tested the binding of ataxin3 to the p97 N-domain fragment, obtaining a KD of 
6.4 ± 1.5 µM (Fig. 2.2B). This is comparable to the affinity observed with full-length p97, and 
suggests that the N-domain is sufficient for ataxin3 binding. We then verified these results using 
ITC, an orthogonal technique that should be free of any artifacts and surface effects associated 
with SPR. The calorimetry experiments yielded KD values of 8.4 ± 0.1 µM and 4.5 ± 0.2 µM for 
ataxin3 binding to full-length p97 and the p97 N-domain respectively (Fig. 2.2, C and D), in good 
agreement with the SPR data. In addition, we derived stoichiometries of 1.38 ± 0.01 and 1.1 ± 0.2 
ataxin3 molecules bound per full-length p97 hexamer and N-domain respectively. The binding 
data are summarized in Appendix 2 Table 1. Thus, we were able to confirm a direct interaction 
between p97 and ataxin3, with low-micromolar affinity, centered on p97’s N-terminal domain. 
 
2.3.2. EM analysis of the p97-ataxin3 complex 
As a homohexamer, p97 can potentially bind up to six cofactor molecules. Our ITC 
experiments suggest that the binding stoichiometry of ataxin3 to the full-length p97 hexamer is 
near 1 : 1. In order to confirm the stoichiometry, we analyzed the complex by negative-stain EM. 
The proteins were incubated together and passed through gel filtration and the complex-
containing fractions were negatively stained and imaged. Purified p97 alone was imaged as a 
control. Our preliminary analyses of the complex fractions revealed an additional blurry density 
at the periphery of the p97 hexamer that was absent in the control (Appendix 2 supplemental Fig. 
S2, A and B). The blurred appearance could result from dissociation of the complex (Appendix 2 
supplemental Fig. S3A), or a flexible association between the two proteins. Additionally, only 
around 5% of the total particles selected showed evidence for complex formation, indicating a 
significant amount of unbound p97 was present. Therefore, in order to stabilize and further enrich 
for the p97-ataxin3 complex, we crosslinked the proteins using glutaraldehyde, followed by 
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affinity chromatography to remove unbound p97 and a final round of gel filtration (Appendix 2 
supplemental Fig. S3B). The fractions containing crosslinked p97-ataxin3 were stained with 1% 
uranyl formate and imaged. Around 7,100 particles were selected from individual micrographs 
(Fig. 2.3A) and sorted into 50 classes. Representative 2D class averages are shown in Fig. 2.3B, in 
which a single distinct projection is visible at one vertex of the p97 hexamer, indicated by the 
white arrows. We confirmed that this additional density corresponds to ataxin3 by imaging 
Nanogold-labelled ataxin3 in complex with p97 (Appendix 2 supplemental Fig. S5). Together with 






Figure 2.3. Visualization of the p97-ataxin3 complex by negative-stain EM. A, electron 
micrographs taken from different portions of the grid, showing negatively-stained hexamers of 
p97 crosslinked to ataxin3; white boxes show particles identified as complexes. The inset (lower 
right) shows a 2× magnified view of two p97-ataxin3 complexes from a third micrograph, and the 
bottom panels show additional raw images of the complex viewed down the 6-fold axis. B, 
representative 2D class averages derived from ~7,100 particles for the p97-ataxin3 complex (left) 
and p97 alone (right). White arrows indicate the bound ataxin3 molecule. 
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2.3.3. Analysis of the p97-ataxin3 binding interface 
We next turned to identifying the portions of the ataxin3 and p97 proteins responsible for 
their interaction. Ataxin3 has a highly-conserved N-terminal Josephin domain that is a cysteine 
protease with DUB activity; the protein also contains a C-terminal polyglutamine region, two 
ubiquitin-interacting motifs (UIMs), and an arginine/lysine-rich p97/VCP-binding motif (VBM) 
(Fig. 2.1B). The VBM has previously been identified as crucial for the p97-ataxin3 interaction (113) 
and is well-conserved across different species (Fig. 2.4A). This motif corresponds to residues 282-
285, and has the sequence RKRR. To determine if this minimal VBM is sufficient for interaction 
with p97, we mutated these residues to ANAA (37) and assessed the proteins’ interaction by SPR, 
which revealed that binding was completely abolished for the mutant (Fig. 2.4D). We also tested 
the binding of various deletion constructs of ataxin3 (Fig. 2.4, B and C). N-terminal fragments 
corresponding to the Josephin domain alone or the Josephin domain plus the UIMs failed to bind 
to p97. However, an ataxin3 N-terminal fragment truncated after the VBM (ataxin31-292, denoted 
hereafter as ataxin3∆C) bound p97 with the same affinity as full-length ataxin3 (Fig. 2.4D). These 
results were supported by ITC experiments that showed full-length ataxin3, ataxin3∆C, and an 
ataxin3220-345 C-terminal fragment (ataxin3∆N) all bind the p97 N-domain with equal affinities (Fig. 
2.4, E and F; Appendix 2 Table 1). Therefore, we conclude that ataxin3’s VBM sequence is 
necessary and sufficient to mediate binding with p97. 
To map the region of p97 that interacts with ataxin3, we first noted that in two recent crystal 
structures, peptides containing either a VBM motif or a related p97/VCP-interacting motif (VIM) 
bind in the same site, within a cleft separating the two lobes of the p97 N-terminal domain 
(64,206,207). Other interacting partners also bind in or near the same site; these include the UBX 
and UBXL domains, whose binding sites overlap the VBM/VIM cleft, despite their possessing very 
different structures (56,58,63,208). To test if ataxin3 utilizes the same binding cleft, we performed 
competition pull-down assays, using a VIM-containing peptide from the ubiquitin ligase gp78 
(64). This peptide prevented His6-tagged ataxin3 from pulling down the p97 fragment containing 
N and D1 domains (Fig. 2.5C), suggesting competition for the same site. We then mutated residues 
lining this binding cleft (Fig. 2.5A), and tested the mutants’ abilities to bind ataxin3 using SPR. 
 43 
Changing residues Tyr143 and Leu72 to alanine completely abolished binding, while the R53A and 
G54W mutations both partially reduced the interaction (Fig. 2.5, B and D). These results 
collectively demonstrate that the VBM of ataxin3 binds in the same inter-lobe cleft of the N-





Figure 2.4. The ataxin3 VBM is necessary and sufficient for interaction with p97. A, alignment 
of the VBMs from different ataxin3 homologs showing conservation across species. B, SDS-
PAGE gel of the different purified ataxin3 constructs used, stained with Coomassie Brilliant Blue. 
C, schematic representation of the ataxin3 constructs shown in B. D, left, representative SPR 
responses for ataxin3 constructs binding to immobilized full-length p97 (for all constructs, analyte 
concentration = 10 µM); right, normalized equilibrium binding responses for the same constructs, 
fit to a one-site binding model (n ≥ 3 for each concentration). The dashed line in the left panel 
represents the response range used to determine the equilibrium fit. E, and F, ITC raw and fitted 
data for the binding of the p97 N-domain to ataxin3 deletion constructs. E, injection of ataxin3ΔC 







Figure 2.5. The inter-lobe cleft of the p97 N-domain forms the ataxin3 binding site. A, 
schematic representation of a p97 protomer showing the approximate positions of mutated 
residues (black arrows) in the N-domain. B, surface representation of the p97 N-domain (PDB 
entry 3TIW (64)) showing the binding cleft that separates the two lobes, and the residues lining 
the cleft that were mutated for binding experiments. Residues in red are the most crucial for 
ataxin3 interaction, since their mutation completely abolishes binding. Mutating the residues in 
orange and yellow partially reduces binding, thus these residues contribute moderately to the 
interaction. C, competition pull-down assays involving His6-tagged ataxin3 and the p97 ND1 
construct, incubated in the presence or absence of a VIM-containing peptide from gp78. D, 
representative SPR responses for 10 µM ataxin3 passed over immobilized wild-type or mutant 





2.3.4. Effect of nucleotides on the p97-ataxin3 interaction 
In the p97 ATPase cycles, nucleotide hydrolysis is accompanied by major conformational 
changes in the hexamer (42,48); hence, it is reasonable to suspect that ataxin3 binding would be 
sensitive to the nucleotide-binding state, and indeed, evidence is available to support this idea 
(113). To quantify this effect, we measured the binding of ataxin3 to p97 in the presence of various 
nucleotides. As shown in Fig. 2.6A, p97 binds ataxin3 in the presence of ATP, ATPgS, and AMP-
PNP, as well as in the absence of added nucleotide. In contrast, ADP significantly inhibits the 
interaction, with an IC50 of 5.5 ± 1.1 µM (Fig. 2.6, A and B). 
There are two nucleotide binding sites per p97 monomer, one each in the D1- and D2-
domains (Fig. 2.6C); the D1-domain binds ADP approximately ten-fold more tightly than the D2-
domain (52,59,177,209). In p97 preparations, a fraction of the D1-domains is typically occupied by 
ADP that is carried through the purification (52). Thus, even when no nucleotide is added, some 
ADP is likely present; added nucleotide is expected to saturate unoccupied sites and compete for 
the pre-occupied sites. To determine which site ADP acts through to disrupt the p97-ataxin3 
interaction, we generated mutations in the Walker A motifs that selectively perturb nucleotide 
binding in each domain, introducing the K251A mutation in the D1-domain and the K524A 
mutation in the D2-domain. The mutant proteins form normal hexamers and exhibit decreased 
ATPase activity, especially the D2 mutants (Appendix 2 supplemental Fig. S6), which is consistent 
with previous findings (52). We used SPR to test the interaction of these mutants with ataxin3 in 
the presence of 0, 10 and 100 µM ADP (Fig. 2.6, D to H). In the absence of ADP, all the mutants 
bound ataxin3 with the same affinity as wild-type p97 (Fig. 2.6D). When ADP was included in the 
binding assay, the mutant in which the D2-domain was disrupted behaved like wild-type p97, 
displaying an ADP-dependent inhibition of ataxin3 binding (Fig. 2.6, E and G). However, mutants 
in which the D1-domain was disrupted (K251A and K251A/K524A) were still able to interact with 
ataxin3, even in the presence of 100 µM ADP (Fig. 2.6, F and H). Thus, ADP’s inhibition of the p97-






Figure 2.6. ADP inhibits the p97-ataxin3 interaction by binding to the D1-domain. A, left, 
SPR responses for 10 µM ataxin3 binding to immobilized full-length p97, in the presence of 
different nucleotides (1 mM), or in the absence of added nucleotide; right, normalized equilibrium 
responses, with and without 1 mM of the indicated nucleotide. The dashed line represents the 
response range used to determine the equilibrium fit. B, Inhibition of ataxin3 binding to 
immobilized full-length p97 by ADP. Ataxin3 concentration was 10 µM; the IC50 value was 
calculated from the nonlinear least-squares regression fit, represented by the solid line. C, ribbon 
representation of the side view of full-length hexameric p97 bound to ADP (PDB entry 5FTK (43)); 
for clarity’s sake, only three of the six protomers are shown. Two protomers are colored light blue 
and light gray, and the third is colored green, cyan, and deep blue (denoting the N-, D1-, and D2- 
domains respectively). ADP is shown in red (ball and stick form), and two conserved Walker A 
residues crucial for ADP binding are shown in yellow (Lys-251 in the D1-domain and Lys-524 in 
the D2-domain). D, normalized equilibrium SPR responses for ataxin3 passed over immobilized 
wild-type p97 and the Walker mutants. E – H, effect of ADP on ataxin3 binding to immobilized 
p97. E, wild-type p97; F, D1 mutant; G, D2 mutant; and H, D1/D2 double mutant. For each p97 
construct, ataxin3 binding is shown in the presence of 0, 10, and 100 µM ADP. For all SPR 




2.3.5. A conformationally-locked form of p97 cannot bind ataxin3 
We next probed the mechanism by which ADP binding inhibits the p97-ataxin3 interaction. 
Recent cryo-EM structures of p97 reveal that when ADP occupies the D1-domain, the N-domain 
is positioned along the side of the hexamer, coplanar to the D1 ring (43); this conformation is 
referred to as the “down-state” (59). In contrast, in the presence of ATP, the N-domain moves 
above the hexamer, to adopt the “up-state.” To test whether this conformational change affects 
ataxin3 binding, we generated the R155C/N387C mutant of p97. These two residues form a 
disulfide bond under oxidizing conditions, which tethers the N-domain to the D1-domain, 
mimicking the down-state, even in the absence of ADP (54) (Fig. 2.7A). In the disulfide-locked 
form, this mutant has very low ATPase activity; activity can be restored by addition of reducing 
agent (Appendix 2 supplemental Fig. S8). Under oxidizing conditions, ataxin3 did not interact 
with the R155C/N387C double mutant; however, under reducing conditions (+ DTT), the 
interaction was restored (Fig. 2.7B). The interaction of wild-type p97 with ataxin3 served as a 
control for any non-specific effects of the reducing agent (Fig. 2.7C). These results suggest that the 
down-state conformation does not allow for ataxin3 binding, and that ADP inhibits the p97-




Figure 2.7. A conformationally-locked form of p97 cannot bind ataxin3. A, ribbon 
representations of the side view of a p97 protomer (PDB entries left, 5FTK and right, 5FTN (43)), 
with the N-, D1-, and D2- domains shown in green, cyan, and deep blue respectively, and the 
two linkers in red. The yellow circles mark the positions of the R155C and N387C mutations that 
form a disulfide bond under oxidizing conditions (− DTT), locking the N-domain in the down-state 
(left). When the disulfide bond is reduced (+ DTT), the N-domain is flexible and free to move to 
the up-state (right), as indicated by the gray arrow. In B and C, the top panels show normalized 
SPR equilibrium responses fit to one-site binding models, and bottom two panels show binding 
to immobilized p97 with and without 7 mM DTT. B, R155C/N387C double mutant; C, wild-type 
p97 (n ≥ 3 for each concentration). The gray dashed lines in the sensorgrams represent the 




2.3.6. Ataxin3 binding is sterically hindered in the down-state conformation of p97 
Crystal structures are available for the p97 N-domain bound to VBM and VIM peptides 
(Protein Data Bank ID codes 5EPP and 3TIW respectively) (64,206). When these structures are 
superimposed on the structure of the full-length p97 hexamer in the down-state, the peptides are 
oriented with their C-termini projecting directly toward the D1 ring of the hexamer (Fig. 2.8A). In 
ataxin3, there are approximately 60 residues located downstream of the VBM (Fig. 2.4C); hence, 
if the ataxin3 VBM adopts the same binding pose as that observed in 5EPP and 3TIW, these 60 
residues at the protein’s C-terminal end would sterically clash against the D1 ring when the p97 
hexamer is in the down-state conformation (Fig. 2.8B). This suggests an explanation for why 
ataxin3 fails to bind when p97 is in the ADP (down-state) form. To test this hypothesis, we 
assessed the binding properties of the C-terminal truncation ataxin3∆C. Unlike the full-length 
protein, ataxin3∆C was still able to bind to p97 in the presence of ADP, and could also bind to the 
R155C/N387C double mutant under both oxidizing and reducing conditions (Fig. 2.8, C and D; 
Appendix 2 supplemental Fig. S9A). These results are consistent with a steric clash between the 
ataxin3 C-terminal region and p97’s D1-ring in the down-state conformation, providing a 






Figure 2.8. Ataxin3 binding is sterically hindered in the down-state conformation of p97. A, 
superposition of the structure of the p97 N-domain bound to the gp78 VIM peptide (PDB entry 
3TIW (64)), and the structure of one protomer of full-length p97 in the ADP-bound form (PDB 
entry 5FTK(43)). The N-, D1-, and D2- domains are shown in green, cyan, and deep blue 
respectively, the gp78 VIM peptide in orange, and ADP in red. The N- and C- terminal ends of 
the peptide are labelled in orange. B, diagram depicting the predicted steric clash of ataxin3’s C-
terminal against the D1-domain in the down-state conformation, and unobstructed binding in the 
up-state. The orientation and color scheme for the p97 subunit are as in A, and ataxin3 is shown 
in orange. C, and D, binding of full-length ataxin3 and ataxin3ΔC to immobilized full-length p97, 
with and without 1 mM ADP. Left panels show normalized SPR equilibrium responses fit to one-
site binding models, and center and right panels show representative sensorgrams (n ≥ 3 for each 
concentration). The gray dashed lines in the sensorgrams represent the response ranges used to 
determine the equilibrium fits. 
  
 51 
2.3.7. ADP does not affect the binding of p97 MSP1 mutants to ataxin3 
MSP1 mutations in p97 alter the equilibrium between the down and up conformations of the 
N-domain (54,59,210). These mutations also increase p97’s ATPase activity (54,91) and lower ADP 
affinity for the D1-domain (59,210). Moreover, the binding of MSP1 mutants to cofactors is 
perturbed relative to that of the wild-type protein, as seen both in cells (53,91,211) and when using 
purified proteins (53,66). Because many of these cofactors bind in the same inter-lobe cleft in the 
N-domain that is used by ataxin3, we sought to determine whether the interaction with ataxin3 is 
altered for MSP1 mutants. 
The pathogenic MSP1 mutations in p97 are principally located in the N-domain, the N-D1 
linker, and the D1-domain. We chose to study one mutation from each of these three regions, 
namely R155H, L198W, and A232E (Fig. 2.9, A and B). The Arg155 mutation is the most prevalent 
and widely-analyzed, and A232E has been linked to early-onset and more severe myopathy and 
dementia (212). L198W was initially detected in MSP1 tissue samples containing rimmed vacuoles 
and cytoplasmic inclusions (174), and its effect on N-domain dynamics has been investigated by 
NMR (197). None of these mutations are at nucleotide-binding sites, or in the binding cleft for 
cofactors (Fig. 2.9B). All three mutant proteins had unaltered oligomeric states and elevated 
ATPase activities as compared to wild-type p97 (Appendix 2 supplemental Fig. S7) (54,67). We 
immobilized them on an SPR sensor chip, using the same oriented-attachment strategy as for 
wild-type p97, and measured their interaction with ataxin3 with and without ADP. In the absence 
of ADP, all three mutants bound ataxin3 with affinities similar to that of wild-type p97 (Fig. 2.9C). 
However, in the presence of ADP the mutants still interacted with ataxin3, unlike the wild-type 
protein (Fig. 2.9D). ADP did not inhibit the interaction with ataxin3, even at concentrations well 
above the reported KD values for the binding of ADP to the D1-domain (52,59,177,209). In wild-
type p97, binding of ADP to the D1-domain triggers the down-state conformation, disrupting the 
ataxin3 interaction; thus, our results indicate that in the MSP1 mutants, ADP binding fails to 
induce the down-state, and therefore does not inhibit the ataxin3 interaction. To test this, we 
introduced the L198W and A232E mutations into the disulfide-locked R155C/N387C variant of 
p97. Both the L198W and A232E versions of the R155C/N387C mutant bound to ataxin3, even 
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under oxidizing conditions (Appendix 2 supplemental Fig. S10, A and B), suggesting that Cys-155 
and Cys-387 are never in close enough proximity to form a disulfide bond and lock the protein in 
the down-state. In line with previous findings (59,85,197), it appears that the mutants rarely adopt 





Figure 2.9. ADP does not inhibit ataxin3 binding to p97 MSP1 mutants. A, schematic 
representation of p97 showing the approximate positions of the three MSP1-related mutations 
(black arrows). B, ribbon representations of the side view of a p97 protomer (PDB entry 5FTN 
(43)), with the N-, D1-, and D2- domains shown in green, cyan, and deep blue respectively, and 
the two linkers in red. The purple circles mark the positions of the R155H, L198W and A232E 
MSP1 mutations in the N-domain, N-D1 linker and D1-domain respectively. The yellow diamonds 
represent the approximate D1 and D2 nucleotide-binding sites, and the light pink ellipse 
highlights the cofactor binding cleft. The view on the left is rotated 60° anti-clockwise around the 
in-plane vertical axis to obtain the view on the right. In C and D, normalized equilibrium SPR 
responses are shown for ataxin3 binding to immobilized wild-type p97 and each of the MSP1 
mutants. Panel C shows ataxin3 binding to wild-type and mutant p97 in the absence of ADP. 
Panel D shows the effects of 0, 10, 100, and 1000 µM ADP on ataxin3 binding to wild-type p97 





Using both SPR and ITC, we have shown that ataxin3 binds p97 with an affinity in the low-
micromolar range. This is comparable to affinities reported for other p97 cofactors, which typically 
range from approximately 0.5 to 20 µM for intact proteins and isolated VIMs, and from 
approximately 50 to 70 µM for isolated VBMs (Appendix 2 supplemental Table S3). Our affinity 
measurements are also consistent with ITC studies that measured the binding of the ataxin3 VBM 
peptide to the p97 N-domain, reporting a KD of 15.6 µM (161). In contrast, our measurements are 
not consistent with a previous report in which SPR was used to derive a substantially higher 
affinity estimate for the p97-ataxin3 interaction (KD ~1 nM) (162). However, as we have shown in 
this work, the p97-ataxin3 system presents challenges when using SPR to measure binding 
affinities, and if mass transport and rebinding events are not accounted for appropriately, the 
affinity and binding kinetics will not be calculated correctly (see Appendix 2 supplemental 
protocols, SPR experimental details and Figs. S12 and S13). The experiments described in 
reference (162) feature high ligand immobilization density, low analyte flow rates, and short 
dissociation times, all conditions likely to promote surface-induced artifacts, which are reflected 
in poor global fits to the kinetic data. Hence, the apparent disagreement between our affinity 
measurements and those reported in the earlier paper may simply reflect differences in data 
analysis, and not a genuine difference in the behavior of the proteins. 
We have also shown that ataxin3 associates with p97 in a stoichiometry of one ataxin3 
molecule per p97 hexamer. Binding stoichiometries vary considerably for different p97 cofactors; 
for example, the p97 hexamer binds to a single Ufd1/Npl4 heterodimer and a single molecule of 
the deubiquitinating enzyme Otu1, but three molecules of p47 (57,58,213). Binding of only a single 
ataxin3 molecule per hexamer may leave room for the binding of other cofactors, or alternately, 
binding of one ataxin3 molecule may prevent interaction with other cofactors. For example, 
overexpression experiments in cell culture suggest that the binding of ataxin3 and Ufd1 to p97 is 
mutually exclusive (37). It is currently still unclear how the binding of a single ataxin3 cofactor to 
the p97 hexamer is sensed by the remaining five protomers, but it seems reasonable to speculate 
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that the sensing mechanism would entail conformational changes involving the N-terminal 
domains. 
Our experiments do reveal how conformational changes control the nucleotide-dependent 
recognition of p97 by ataxin3. p97 binds many different cofactors, some of which have 
antagonistic functions; therefore, cofactor binding must be carefully controlled. This control may 
be exerted through different mechanisms, such as post-translational modification (214) or 
upregulation of cofactor levels (78). In the case of ataxin3, binding is clearly regulated by the 
nucleotide binding state of the p97 hexamer, as demonstrated by pull-down experiments using 
cell lysates and recombinant proteins (113). A similar, albeit less pronounced, nucleotide-based 
control of binding has also been reported for the cofactor p47 (66). We have probed nucleotide 
control of ataxin3 binding to p97 using purified proteins, confirming that the two proteins 
associate in the presence of ATP or the absence of nucleotide, but not in the presence of ADP. We 
propose a mechanism to explain this behavior, drawing upon recent cryo-EM studies that reveal 
that different nucleotides give rise to distinct p97 conformations in which the N-terminal domain 
moves relative to the D1-ring (43). Taken together with our data, these experiments suggest that 
an ADP-driven downward movement of the N-terminal domain dislodges ataxin3 by causing a 
steric clash between the D1-domain and ataxin3’s C-terminus. Since ataxin3 uses a binding site on 
the N-terminal domain that is also used by other p97 cofactors, this steric dislodgement 
mechanism may also occur with other cofactors, depending upon their geometry of binding. 
This model helps to explain how recognition of ataxin3 is altered in MSP1 mutants of p97. In 
cells, MSP1 mutants bind significantly elevated amounts of ataxin3 as compared to wild-type p97 
(53). We show that the mutant proteins’ affinities for ataxin3 are unchanged; however, whereas 
ADP abolishes ataxin3 binding to wild-type p97, it does not inhibit ataxin3 binding for the 
mutants. Hence, the elevated ataxin3 binding observed in cells can be explained by a failure of the 
mutant p97 proteins to release ataxin3, even after ATP has been hydrolyzed to ADP. This atypical 
ataxin3 binding reflects defective inter-domain communication in the MSP1 mutants, which 
makes them unable transduce the ADP-bound signal from the D1 to the N-domain. The failure to 
release ataxin3, even in the presence of ADP, could perturb normal processing of ubiquitinated 
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substrates, possibly by preventing other cofactors from binding; for example, MSP1 mutants that 
bind elevated levels of ataxin3 bind reduced amounts of the ubiquitin ligase E4B (53). 
Additionally, an increased residence time on p97 might disrupt ataxin3’s normal patterns of sub-
cellular localization, since residues within ataxin3’s VBM form a functional nuclear localization 
sequence (215). Binding to p97 may mask this sequence and reduce nuclear levels of ataxin3. 
Notably, ataxin3 is not the only cofactor for which binding is perturbed in the MSP1 mutants; 
nucleotide control of p47 binding is also altered in the mutants (66), which suggests that the ADP-
driven conformational changes may be a general mechanism for regulating cofactor binding. 
Ataxin3 is thought to coordinate with p97 to maintain the flux of proteins through ERAD 
(164); however, its specific role has not been elucidated at the molecular level. In ERAD, p97 acts 
as a segregase, coupling ATP hydrolysis with the removal of ubiquitinated substrates from the 
ER. The importance of ubiquitination is quite clear—substrates must be ubiquitinated in order for 
p97 to be recruited to the site of protein dislocation (156), and non-ubiquitinated substrates are 
not efficiently unfolded and translocated by p97 (163,216). Furthermore, if the substrate is to be 
targeted to the proteasome, it should remain ubiquitinated once released from p97. However, the 
function of deubiquitination in ERAD is less clear, and thus the part played by ataxin3 has not 
been immediately obvious. One possibility is that ataxin3 edits non-K48 ubiquitin linkages that 
will not be efficiently recognized by the proteasome; this is consistent with the report that the 
enzyme recognizes mixed-linkage ubiquitin chains (117). Another possibility is that ataxin3 serves 
to trim excessively long ubiquitin chains to a minimum length necessary for proteasomal 
degradation. Such an activity would allow for recycling of ubiquitin molecules; it might also ease 
the burden on p97, since it appears that ubiquitin chains attached to substrates must be threaded 
through the central pore of the p97 hexamer, along with the substrate (163). Such a trimming 
activity for ataxin3 would be consistent with its observed substrate specificity, which is skewed 
toward longer ubiquitin chains. In fact, ataxin3 is quite inefficient at cleaving tetra-ubiquitin and 
smaller chains (99), which coincides with the minimum size required for efficient proteasome 
targeting (121). Thus, one possible model is that p97 is first recruited to a ubiquitinated substrate 
by the cofactors Ufd1/Npl4, after which ataxin3 binds (possibly triggering release of Ufd1/Npl4). 
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The ataxin3 then can trim excessive ubiquitin chains and/or remove incorrect linkages as the 
substrate is being translocated. Our EM results suggest that the linkage between ataxin3 and p97 
is a flexible one, which could allow for continuous processing of ubiquitin chains even as the 
substrate is being threaded through the pore. Once the p97 catalytic cycle is finished and ATP is 
hydrolyzed to ADP in the D1-ring, the ataxin3 would be released. Given that the D1-ring only 
needs to undergo one or a few hydrolysis cycles in order for an entire substrate to be processed 
(163), ataxin3 may be able to fully complete its task during a single ATP/ADP cycle. It is also 
possible that ataxin3, once dislodged from p97, can re-engage with ubiquitinated substrates that 
have been released from p97, possibly facilitating their hand-off to shuttling factors like Rad23 
and Dsk2 for delivery to the proteasome (217,218). 
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CHAPTER 3: Ataxin3 is Activated by Non-Covalent Interactions with Ubiquitin 
 
3.1. Introduction 
The modification of targets by ubiquitin is a powerful and versatile form of regulation. 
Ubiquitination can brand a protein for destruction, alter its intracellular location, or regulate its 
function. It is not surprising that the ubiquitin molecule is central to a diverse range of cellular 
processes, from transcription, translation, and signal transduction, to protein trafficking, organelle 
assembly, and cell cycle control (15-18). Typically, ubiquitination involves a covalent modification 
of other proteins. There have been reports however, of non-covalent ubiquitin control (219-221), 
wherein the ubiquitin signal is recognized and processed by ubiquitin-binding domains (UBDs). 
UBDs form transient and non-covalent interactions with both single molecules and chains of 
ubiquitin. Over 20 families of UBDs have been identified; most of them encode α-helical 
structures, including the ubiquitin-associated domain (UBA) and the ubiquitin-interacting motif 
(UIM) (221-223). 
Most protein-protein interaction interfaces are formed by hydrophobic contacts, and the 
UIMs are no exception. The highly-conserved short peptide sequence of the UIM binds mono- 
and poly-ubiquitin primarily via hydrophobic residues that recognize the Leu-8/Ile-44/Val-70 
hydrophobic patch on ubiquitin (224,225). Proteins often contain multiple copies of the UIM 
connected by linkers of varying lengths. These UIM repeats typically bind ubiquitin in a 
cooperative manner (226,227), and the binding can be specifically altered or disrupted by 
mutation of conserved residues within the UIM (101,119,228). Some proteins lack bona fide 
ubiquitin-binding sites like UIMs, but are still able to bind ubiquitin non-covalently. Often, these 
non-canonical binding sites are merely exposed hydrophobic patches or aromatic clusters on the 
protein surface that can facilitate short-lived, low-affinity interactions with hydrophobic residues 
on ubiquitin (102). This poses a challenge to identify and characterize such sites, due to the 
possibility of non-specific or irrelevant interactions with ubiquitin, and their scant sequence 
homology with other known binding interfaces. 
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The binding of ubiquitin to targets, both covalently and non-covalently, signals different 
outcomes for these targets in various pathways. DUBs are enzymes that reverse or switch off the 
signaling message from ubiquitin or poly-ubiquitin chains (Fig. 1.2). They function by cleaving 
ubiquitin from substrates, editing the length or type of ubiquitin chains, and disassembling 
untethered poly-ubiquitin chains to recycle ubiquitin molecules (reviewed in (97,229,230)). There 
are nearly 100 DUBs encoded by the human genome (230), and relatively little is known about 
their precise function or regulation. DUB activity may be regulated at the level of transcription or 
degradation, and sometimes by substrate-induced conformation changes, complex formation or 
post-translational modifications (97,229-231). 
DUB activity is sometimes controlled by its own ubiquitination (reviewed in (232)). For 
example, the ubiquitination of K157 on UCH-L1 decreases its activity, while the opposite is 
observed for ataxin3 and Josephin1 on their K117 residues (120,233,234). To date, there are no 
reports of whether non-covalent ubiquitin interactions also modulate DUB activity. The 
possibility of this type of regulation is suggested by studies of other enzymes involved in the 
ubiquitin pathways. A ubiquitin-binding site on the E2 ligase UBE2B, remote from its active site, 
was first described in 1999 (235); since then, many other E2 and E3 ligases were found to be 
controlled by low-affinity interactions with ubiquitin (219). The RING domain in some E3s 
contacts the ubiquitin molecule attached covalently to the associated E2, which is necessary for 
ubiquitin transfer activity (236). Binding to ubiquitin stimulates the activity of Parkin, another 
important E3 ligase (237). The UbcH5 family of E2s binds ubiquitin at a site distant from the active 
site to promote self-assembly, and eventually, the formation of ubiquitin chains (238). It is now 
clear that ubiquitin is not merely a substrate, but also functions as an allosteric regulator of E2 and 
E3 activity. Finally, non-covalent interactions with ubiquitin can even regulate proteins unrelated 
to ubiquitin pathways. The tyrosine phosphatase PtpA from Mycobacterium tuberculosis is 
activated by ubiquitin binding (239), and proteolysis by the metalloprotease IDE, the insulin-
degrading enzyme, is inhibited by its binding to ubiquitin (240). Here we report that the catalytic 
activity of the DUB ataxin3 is stimulated by a direct interaction with ubiquitin and ubiquitin 
conjugates. 
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Ataxin3 is the founding member of the Josephin isopeptidase family, and possesses an N-
terminal catalytic Josephin domain, followed by two UIMs, a polyQ tract that is expanded in the 
neurodegenerative disorder SCA3, and a third C-terminal UIM that is only present in certain 
splice variants (241) (Fig. 2.1 and Fig. 3.3A) (described in detail in section 1.3). The DUB contacts 
ubiquitinated substrates via its first two UIMs (111), and exhibits a strong affinity for K48- and 
K63-linked poly-ubiquitin chains of four or more subunits; however, ataxin3 preferentially 
cleaves K63- and mixed-linkage chains in vitro (117), and has endo-type activity (116). It thus 
believed to function as a chain-trimming DUB. The UIMs enhance this property (34) and critically 
regulate ataxin3’s cleavage preference, as well as its ability to bind ubiquitin (117). Other than the 
UIMs, there are two additional ubiquitin-binding sites on ataxin3 that reside in the Josephin 
domain, denoted site 1 and site 2 (Fig. 3.1) (102,115,118,122). Site 1 is the active site that orients the 
substrate ubiquitin molecule for cleavage by the catalytic triad, and is indispensable for DUB 
activity (118). Site 2 is located on the opposite face of the Josephin and overlaps with the Rad23B 
binding patch. This site may be involved in the release of ubiquitin or ubiquitinated substrates via 
competitive Rad23B interactions. Both sites promote non-covalent, low affinity binding to 
ubiquitin molecules as described in (102). 
Ataxin3 function is implicated in ubiquitin-dependent protein quality control (see section 
1.3). In its capacity as a DUB, it significantly contributes to ERAD, coordinating with the p97 
ATPase to target substrates to the proteasome (37,38). Additionally, its DUB activity appears to 
be neuroprotective against toxic proteins (140), and is also necessary for aggresome formation 
(36). However, while ataxin3 clearly functions as a DUB in vivo, its in vitro activity is less efficient 
than that of structurally similar proteases like USP7 and UCHL3. Todi et al. demonstrated that 
ataxin3 is moderately activated by ubiquitination of its Josephin domain (120), and indeed, ataxin3 
is observed to be ubiquitinated in cells (242). Additionally, its ubiquitination increases during 
cellular stress (120), when there is a higher requirement for its activity. The UIMs mediate the 
ubiquitination of ataxin3 (119), and coordinate with the Josephin by presenting ubiquitin chains 
to the catalytic site, and restricting the types of linkages cleaved (120). 
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The Josephin and the UIMs are also thought to cooperate with each other in other ways, 
linking ubiquitin recognition and binding to proteolysis. The UIMs may recruit ataxin3 to 
ubiquitinated substrates, orient these substrates relative to the Josephin, or fine-tune the 
Josephin’s editing function. Here we report a robust modulation of ataxin3 DUB activity via the 
UIMs and the ubiquitin-binding sites on the Josephin. We demonstrate that ubiquitin, and more 
specifically His6-tagged ubiquitin, directly stimulates enzymatic activity for both full-length 
ataxin3 and the isolated Josephin domain; this magnitude of stimulation far exceeds that observed 
as a result of ataxin3 ubiquitination (120), and has not been reported previously. Our results 
suggest that the cellular functions of ataxin3 may be regulated via non-covalent, transient 
interactions with ubiquitin. 
 
 
Figure 3.1 Structure of the ataxin3 Josephin domain bound to two ubiquitin molecules. (PDB 
entry 2JRI (102)) The Josephin is shown in orange, and the two ubiquitin molecules are depicted 
in light green and teal. The key residues in the ubiquitin-binding site 1 (cyan ellipse) are shown in 
cyan, and those in site 2 (deep blue ellipse) are shown in deep blue. The catalytic triad is 
highlighted by the yellow triangle and the three crucial residues are shown in red. The C-terminal 
end of ubiquitin molecule 1, which would be hydrolyzed by the active site residues, is visible 
within the catalytic triad yellow triangle.   
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3.2. Experimental Procedures 
3.2.1. Reagents 
Enzymes for cloning were purchased from New England Biolabs (Ipswich, MA). PCR 
primers were purchased from Integrated DNA Technologies Inc. (Coralville, IA) and sequencing 
of constructs was performed by Genewiz (South Plainfield, NJ). All chemicals were from Sigma-
Aldrich (St. Louis, MO) unless otherwise stated, and media components were purchased from 
Fisher Scientific. Chromatography columns were obtained from GE Healthcare, and the ubiquitin-
AMC was purchased from Boston Biochem (Cambridge, MA). 
 
3.2.2. Cloning and mutagenesis 
Human ataxin3 proteins were cloned into the pETHSUL vector to generate N-terminal His6-
tagged SUMO fusion constructs, under T7 promoter control (see section 2.2.2 for ataxin3 construct 
details), and ubiquitin was cloned into the pRSETA and pETCH vectors (99,198). The following 
constructs were used in this work: full-length ataxin3 (aa 1-345), ataxin3 Josephin domain (aa 1-
190), ataxin3 site-2 mutant (aa 1-345), ataxin3 UIM mutant (aa 1-345), ubiquitin (aa 1-76), and 
ubiquitin-His6 (aa 1-86). The site-2 mutant (W87K) and the UIM mutant (S236A/S256A) were 
generated by one-step PCR-mediated site-directed mutagenesis (199), using full-length 
pETHSUL-ataxin3 as the template. The C-terminal His6-tagged ubiquitin was cloned into the 
pETCH vector (198) by Xba1/Xma1 digestion and ligation. Primer sequences and additional 
details are provided in Appendix 3 supplemental tables 1 and 2. Cloning, mutagenesis, and 
plasmid amplification were performed using the Escherichia coli Mach1 strain (Invitrogen). 
 
3.2.3. Protein expression and purification 
Detailed information about the preparation of ataxin3 constructs is given in section 2.2.3 and 
Appendix 2 supplemental protocols. The site-2 and UIM mutants were expressed and purified by 
the same protocol as wild-type ataxin3.  
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The ubiquitin constructs were expressed in E. coli Rosetta (DE3) cells (Novagen). The 
transformed cells were grown in auto-inducing media ZYP-5052 (243), after which, the cells were 
harvested by centrifugation at 5,000 × g for 30 min. The cell pellets were then resuspended in water 
and flash-frozen. Preceding purification, the pellets were rapidly thawed under running water 
and resuspended in 1× PBS, pH 7.4, 10 mM MgCl2, and 1 µg/ml DNAse and RNAse. All cells were 
lysed by at least two passes through an Emulsiflex-C5 homogenizer (Avestin, Ontario, Canada) 
at approximately 173 MPa. Following clarification at 18,000 × g, the cell lysate was treated with 
0.5% v/v perchloric acid, and stirred for 30 min at room temperature. The precipitated slurry was 
then centrifuged again at 18,000 × g. For the untagged ubiquitin construct, the supernatant was 
dialyzed against 20 mM sodium acetate, pH 5.2, and loaded onto a HiTrap SP HP column 
equilibrated in the same buffer, for cation-exchange chromatography. Ubiquitin was eluted over 
20 column volumes of buffer at the same pH, using a 0–300 mM gradient of NaCl. The pooled 
fractions were concentrated to 20–25 mg/ml using an YM3 Centricon device, and aliquots were 
flash frozen and stored at –80°C. For the UbHis6 construct, the protein was first dialyzed against 
50 mM sodium phosphate, pH 8, 250 mM NaCl, 20 mM imidazole, and loaded onto a HiTrap 
Chelating HP column, for isolation by immobilized-metal affinity chromatography. After elution 
over a 20–300 mM gradient of imidazole, the protein was further purified by cation-exchange 
chromatography, and concentrated as described above.  
 
3.2.4. Fluorometric UbAMC assays 
Assays were performed on a Fluoromax-3 spectrofluorimeter (Jobin Yvon Horiba), at room 
temperature, in a buffer containing 50 mM Tris, pH 7.5, 250 mM NaCl, 5 mM DTT, in a total reaction 
volume of 200 µl. Fluorescence (excitation: 345 nm, emission: 445 nm) was measured at 5 s 
intervals for 10 min. For experiments with full-length ataxin3 (wild-type and mutants), 1 µM 
UbAMC substrate and 20 nM enzyme were used. For experiments involving the isolated Josephin 
domain, the substrate and enzyme concentrations were 2 µM and 50 nM respectively. The 
concentration of ubiquitin or ubiquitin-His6 used in all reactions was 75 µM. The initial reaction 
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rates were calculated from linear fits of the fluorescence vs. time data. All rates are reported as an 
approximate fold increase over basal wild-type hydrolysis rate. 
 
3.3. Results 
3.3.1. Ubiquitin and ubiquitin-His6 stimulate ataxin3 DUB activity 
There is increasing evidence that the function of the E1/E2/E3 machinery in attaching 
ubiquitin to substrates, and assembling poly-ubiquitin chains, is regulated by the binding of 
ubiquitin itself at noncatalytic sites on these enzymes (219). It is possible that such interactions 
also control the detachment of ubiquitin from substrates by DUBs. Since ataxin3 specifically 
associates with ubiquitin and ubiquitin chains (34,101,102,117), we hypothesized that these 
interactions might regulate its enzymatic activity. 
 
 
Figure 3.2 Linkages in different ubiquitin substrates. Comparison of the structures of Ub-
AMC, UbHis6, and the true isopeptide linkage in the vicinity of the scissile bond. The ubiquitin 
molecule is depicted by the teal sphere. The site of DUB cleavage is indicated by the red bolt. 
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Ataxin3 DUB activity has been extensively studied in vitro (34,99,100,116,117,120), and has 
been characterized previously using the artificial DUB substrate ubiquitin-7-amino-4-
methoxycoumarin (Ub-AMC), which consists of the fluorophore AMC conjugated to the C-
terminal of ubiquitin by an amide linkage (Fig. 3.2). Ub-AMC is weakly fluorescent, but exhibits 
increased fluorescence when hydrolyzed to free AMC; this facilitates a sensitive and continuous 
monitoring of substrate cleavage by the DUB under consideration. Using this assay, we first 
measured the DUB activity of purified wild-type ataxin3 alone, under steady-state conditions 
(using 20 nM ataxin3 with 1 µM Ub-AMC substrate), and calculated an initial Ub-AMC hydrolysis 
rate of 5.5 ± 1.3 fM/sec (Fig. 3.3B). We then tested the effect of a large excess of mono-ubiquitin (75 
µM) on ataxin3 DUB activity, using both native and His6-tagged ubiquitin constructs (hereafter 
denoted Ub and UbHis6 respectively). The addition of Ub caused a 3-fold increase in the 
hydrolysis rate, while UbHis6 greatly stimulated DUB activity and induced a 40-fold increase in 
hydrolysis (Fig. 3.3B); such a robust up-regulation of DUB catalysis has not been described 
previously. We performed the experiments in the absence of ataxin3 to control for any spurious 
fluorescence from Ub or UbHis6, and detected no increase in the signal (Appendix 3 Fig. 1). In 
addition, we observed no stimulation of DUB activity with a His6-tagged control protein MBP-
His6, added to the reaction at the same concentration as Ub and UbHis6 (Appendix 3 Fig. 2). 
Interestingly, UbHis6 also functions as a DUB substrate for ataxin3 (Fig. 3.2), and the fusion 
protein is slowly cleaved to release the His6-tag, but this hydrolysis cannot be detected in our 







Figure 3.3 Ubiquitin constructs stimulate full-length ataxin3 and the isolated Josephin 
domain. A, schematic representation of full-length ataxin3 and the Josephin construct showing 
the Josephin domain (orange), two UIMs (green), and the polyQ repeat region (grey). The scale 
below the full-length representation shows length in amino acids. B and C, stimulation of ataxin3 
by Ub (blue) and UbHis6 (black) as measured by Ub-AMC cleavage assays; B, full-length ataxin3, 
or C, the isolated Josephin domain (n ≥ 3 for each reaction). The left panels are representative 
plots showing the increase in fluorescence over time, and the right panels show the initial reaction 
rates normalized to the basal hydrolysis rate (red). 
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3.3.2. Effect of Ub and UbHis6 on the isolated Josephin domain 
We then investigated the effect of Ub and UbHis6 on the isolated Josephin. The Josephin 
domain hosts the enzymatic cleft and thereby forms the catalytic center of ataxin3. We tested the 
activity of the isolated Josephin domain construct (using 50 nM enzyme and 2 µM Ub-AMC), and 
found that it hydrolyzes Ub-AMC at the rate of 2.7 ± 1.8 fM/sec (Fig. 3.3C). On adding Ub and 
UbHis6, the reaction rate was increased 3-fold and 10-fold respectively (Fig. 3.3C), a similar, albeit 
less pronounced stimulation as that observed for full-length ataxin3.  
Thus, UbHis6 induces a 40-fold increase in full-length activity, but only a 10-fold stimulation 
for the isolated Josephin domain. There are two ubiquitin-binding sites (denoted site 1 and site 2; 
Fig. 3.1) that reside in the Josephin domain (102). However, since the Josephin domain lacks the 
C-terminal half of the protein, along with all the binding motifs therein, it is likely that one of 
those missing sites may account for the observed differences in stimulation. Indeed, the motifs 
that promote ataxin3 binding to ubiquitin chains, the UIMs, are absent in the Josephin construct 
(Fig. 3.3A). 
We hypothesize that UbHis6 binds to multiple ubiquitin-binding sites on ataxin3, and 
thereby enhances ataxin3 DUB activity. As characterized previously by ITC, mono-ubiquitin 
binds sites 1 and 2 in the Josephin with affinities of 47 ± 13 µM and 43 ± 10 µM respectively (102). 
An apparent KD of 97 ± 17 µM was also derived for ubiquitin binding to the isolated UIMs, through 
NMR titration experiments (226), although this may be a rough estimate of a much more complex 
interaction. Such low affinity interactions, however, are consistent with that observed in other 
DUBs and ubiquitin-binding domains (244,245), especially in the case of transient ubiquitin 
function where the molecule is not a permanent binding partner. The concentrations of Ub and 
UbHis6 in our assays were calculated based on the above-mentioned affinities, in order to saturate 
all binding sites. 
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3.3.3. Multiple ubiquitin-binding sites modulate ataxin3 activity   
We next sought to test our hypothesis, specifically whether UbHis6 stimulates ataxin3 
activity directly by binding to the multiple non-covalent ubiquitin-binding sites. Nicastro et al. 
reported the solution structure of the Josephin bound to two ubiquitin molecules (102) that 
revealed both the location of these binding sites, and the residues involved in their interactions 
with ubiquitin (Fig. 3.1). Site 1 is the DUB active site and exploits an induced fit mechanism to 
bind ubiquitin, involving a flexible helical hairpin. This site is critical for positioning the substrate 
adjacent to the catalytic triad. Site 2 is on the opposite side of the Josephin domain as the catalytic 
cleft, and overlaps with the Rad23B binding site. Mutation of specific residues in either site 
selectively abrogates their interaction with ubiquitin (I77KQ78K for site 1 and W87K for site 2) 
(102,118).  
We reasoned that a site-1 mutant would not be useful for our analyses, since it does not 
possess any measurable DUB activity (118,246). Instead, we generated and tested the site-2 mutant 
of full-length ataxin3 (Fig. 3.4A). Adding UbHis6 to the reaction stimulated a 13-fold increase in 
the hydrolysis rate of the site-2 mutant, a much-reduced stimulation compared to that observed 
with the wild-type (Fig. 3.4B). In addition, a distinct lag phase was noticeable for the cleavage 
reaction, which was either absent or too short-lived to be detected for the wild-type (Fig. 3.4B). 
The site-2 mutant also demonstrated an overall lower basal rate of hydrolysis as compared to the 
wild-type. This is consistent with earlier studies using K48-linked penta-ubiquitin and mixed-
linkage tetra-ubiquitin chains as substrates (118). However, in those studies, the site-2 mutant 
exhibited a 70% reduction in the basal rate of chain cleavage as compared to the wild-type, while 
our mutant is 90% less active as measured using the Ub-AMC assay. 
After testing the ubiquitin-binding site on the Josephin domain, we next analyzed the 
contribution of the UIMs. The two short tandem motifs consist of a conserved core sequence 
eeexLxxAxxxSxxe (e = negatively charged residue, x = any residue) (Fig. 3.4A) (247), and bind 
ubiquitin in a cooperative manner (226). Mutation of the conserved serine residues to alanines in 
both UIMs considerably diminishes binding to tetra-ubiquitin (101) and to ubiquitinated proteins 
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(119). Given that the affinity of the UIMs for mono-ubiquitin is already low (226), the S–A 
mutations should successfully abolish any binding to our UbHis6 protein. We thus generated the 
full-length ataxin3 UIM mutant (S236A/S256A) (Fig. 3.4A), and tested for the stimulation of its 
activity. UbHis6 stimulated the UIM mutant activity to an even smaller extent than that observed 
for the site-2 mutant (Fig. 3.4C); the calculated hydrolysis rate was only 6-fold higher compared 
to the 40-fold stimulation observed in the wild-type. The basal activity of the UIM mutant was 
also found to be lower than that of the wild-type, and the initial lag phase was even more 
pronounced as compared to that observed with the site-2 mutant. 
Since neither the site-2 nor UIM mutations affect the expression or stability of the protein 
(101,102), it is unlikely that our observations are due to structural defects in the mutant enzymes. 
From our experiments, it is evident that both the Josephin site 2 and the UIMs contribute to the 
stimulation of ataxin3’s basal DUB activity, induced by the binding of UbHis6 at these sites. 
Moreover, the large increase in hydrolysis rate observed for the wild-type is greater than the 






Figure 3.4 Reduced stimulation of ubiquitin binding-site mutants. A, schematic 
representations of the ataxin3 site 2 mutant (above), and UIM mutant (below), using the same 
color scheme as Fig. 3.3A. The residue mutations for both constructs are mentioned in red, and 
the site of each mutation is depicted with a black cross. In the UIM mutant, the critical Ser residue 
within each UIM sequence is indicated in bold face. B and C, stimulation of wild-type (WT) and 
mutants (MT) by UbHis6 as measured by Ub-AMC cleavage assays; B, ataxin3 WT and site 2 MT, 
or C, ataxin3 WT and UIM MT (n ≥ 3 for each reaction). The left panels are representative plots 
showing the increase in fluorescence over time, and the right panels show the initial reaction 
rates normalized to the basal hydrolysis rate of the wild-type. The wild-type data shown in B, and 
C, is the same as that shown in Fig. 3.3B. 
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3.3.4. UbHis6 also enhances ataxin3 SRT mutant activity  
Ataxin3 activity differs significantly from that of its homolog AT3L, with the latter exhibiting 
considerably higher cleavage of a variety of substrates (99). When specific residues in ataxin3 are 
mutated to the corresponding residues in AT3L, the DUB activity of the resulting chimera is much 
enhanced and nearly equal to that of AT3L (99); these mutations comprise S12F, R59L and T60A, 
which together form the triple SRT mutant. None of these residues lie in the enzymatic cleft or at 
any known ubiquitin-binding site, although the Ser-12 residue is adjacent to the active site and 
may enhance substrate affinity (Fig. 3.5A).  
In order to test whether Ub and UbHis6 would further stimulate its activity, we generated 
the SRT mutant in the full-length ataxin3 construct (Fig. 3.5B). Consistent with previous results, 
we observed a large increase in basal SRT mutant activity, with a hydrolysis rate of 165.6 ± 9.4 
fM/sec, which corresponds to a 30-fold increase over basal wild-type activity (Fig. 3.5C). On 
adding Ub and UbHis6, the rate was further increased, measured as a 45- and 60-fold stimulation 
respectively (Fig. 3.5C).  
Thus, the basal DUB activity of the SRT mutant, which is already significantly enhanced, can 







Figure 3.5 Stimulation of ataxin3 SRT mutant by ubiquitin constructs. A, structure of the 
ataxin3 Josephin/ubiquitin complex (PDB entry 2JRI), using the same color scheme as Fig. 3.1. 
The three residues that are mutated are shown in purple. R59 and T60 are on the helical hairpin, 
and S12 is near the active site cysteine. B, schematic representations of the ataxin3 SRT mutant. 
The three mutations are mentioned in red, and the site of each mutation in the Josephin domain 
is indicated with a purple star. C, stimulation of the SRT mutant by Ub and UbHis6, as measured 
by Ub-AMC cleavage assays (n ≥ 3 for each reaction). The left panel is a representative plot 
showing the increase in fluorescence over time for the SRT mutant alone (red), and with Ub (blue), 
and UbHis6 (black). The right panel shows the initial reaction rates in the presence and absence of 
ubiquitin constructs, for the wild-type (WT), and the SRT mutant (MT), normalized to the basal 




Using a continuous assay based on the fluorogenic substrate Ub-AMC, we have shown that 
the DUB activity of full-length ataxin3 is stimulated by non-covalent interactions with either Ub 
or UbHis6. Although these are low-micromolar affinity interactions, they are able to elicit a 3-fold 
increase in the rate of substrate cleavage in the presence of Ub, and a nearly 40-fold increase with 
UbHis6. It is not clear why the stimulation by UbHis6 is so much greater than that observed with 
Ub alone. Unlike Ub, the UbHis6 construct is a substrate of ataxin3; this may be significant in the 
context of allosteric regulation. In fact, the scissile bond in UbHis6 is more similar to the naturally 
occurring isopeptide linkage in physiological substrates, than the Ub-AMC bond (see Fig. 3.2), 
and UbHis6 could conceivably compete for the active site on ataxin3, thus reducing or blocking 
the fluorescent signal in our assays. However, the robust increase in the signal with UbHis6 
indicates that the effect of the enhancement is substantial enough to overcome any competitive 
effects. Alternately, it may be a non-specific effect mediated by the His6-tag, but it is unlikely due 
to the His6 tag alone, given that the MBP-His6 control does not stimulate activity. Future 
experiments with different ubiquitin conjugates will be useful in revealing the molecular 
determinants of this stimulation. 
Ub and UbHis6 also enhance the activity of the isolated N-terminal Josephin domain, but to 
a lesser extent than that observed for the full-length. This suggests that along with the Josephin 
site 2, the UIMs that are absent in the isolated Josephin construct are also required for the complete 
stimulation of ataxin3’s DUB activity. We therefore generated mutants in which ubiquitin binding 
at one or the other of the two sites was compromised, and found that both mutants exhibited 
reduced stimulation by UbHis6, indicating that the effects of binding in the two sites are additive. 
Interestingly, an initial lag phase was observed for both mutants. Lag phases are characteristic of 
many enzyme-catalyzed reactions; often, the lag marks a conformational change within the 
enzyme (248), a switch from an inactive or less active to a more active form (e.g. a conventional 
lag is observed during the activation of the hydrogenase class of enzymes (249)). Conformational 
changes may be induced by the binding of the substrate itself or by the slow association of 
allosteric ligands, like the binding of glucose or small-molecule activators to human glucokinase, 
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which is visible as a distinct lag phase (250,251). In our assays, the lag was either absent or too 
rapid to detect for the wild-type, and was more pronounced for the UIM mutant than for the site-
2 mutant. Possibly, the UIMs convey the UbHis6-bound signal to the active site more quickly or 
more efficiently than site 2, and when both sites are available as in the wild-type, the signal is 
transduced quickly enough to mask the lag phase. 
Since DUBs are proteases, it is crucial that their activity and specificity be regulated, to avoid 
the inadvertent cleavage of non-substrate molecules in the cell. DUBs are often controlled by 
components of the pathways in which they function, for example, caspase-3 inactivates the DUB 
USP7, which functions in apoptosis (252). Several DUBs are modified by ubiquitin (253-255); this 
typically involves the covalent conjugation of ubiquitin, which regulates their degradation. In the 
case of ataxin3, ubiquitination enhances DUB activity (120), but this stimulation only corresponds 
to a 4-5-fold increase in activity, and is not as robust as the stimulation we observe from the non-
covalent binding of ubiquitin. Based on our findings, we propose a novel form of DUB regulation, 
wherein the binding of Ub and UbHis6 to the Josephin site 2 and the C-terminal UIMs in ataxin3 
causes conformational changes that enhance catalysis.  
A conformational switch has been previously suggested for ataxin3 in a mechanism 
involving a helical hairpin in the Josephin (19,115). The three published solution structures of the 
Josephin alone (PDB entries 2AGA, 2DOS and 1YZB) show the hairpin in significantly different 
conformations, involving closed, intermediate and open states  (115,116,122). Validation 
calculations and SAXS measurements have since disproved the 2AGA structure (256), however, 
computational analyses using molecular dynamic simulations support the possibility of an 
analogous three-state pathway (Fig. 3.6) (257,258), and suggest that different states may be 
stabilized under different conditions. In structures of the Josephin-ubiquitin complex from both 
ataxin3 and the closely related AT3L protein (PDB entries 2JRI (102) and 3O65 (99) respectively), 
the hairpin is in the open conformation, which clearly accommodates the ubiquitin molecule at 






Figure 3.6 Comparison of the various ataxin3 Josephin structures. In all three structures, the 
Josephin is shown in grey, and the helical hairpin arm is shown in orange. The arm assumes 
different conformations in each of the structures; it is closer to the Josephin in 2DOS, and 
extended away from the Josephin, in what is termed as the “open state”, in 1YZB. The 2JRI 
structure shows a marginal extension of the arm, as it appears to grasp the ubiquitin molecule 
(semi-transparent representation colored green) bound at site 1. 
 
It is tempting to speculate that ubiquitin binding to site 2 either induces or stabilizes the open 
conformation and thus, facilitates better substrate access to site 1 (Fig. 3.7). Alternately, binding at 
site 2 may merely position a chain for cleavage at site 1, increase substrate affinity at site 1, or 
facilitate substrate hand-off to site 1. The significance of these dual binding sites is yet to be 
elucidated, however, the Pastore group has shown that their respective positions on the Josephin 




Figure 3.7 Model depicting conformational regulation of the helical arm by ubiquitin. The 
Josephin domain is shown in orange, and the ubiquitin molecules are shown as teal spheres. The 
ubiquitin-binding sites are shown in cyan (site 1), and deep blue (site 2). The helical hairpin arm 
is initially folded against the Josephin domain in the closed state, which is computed to be the 
most energetically favorable configuration (257). In this state, the arm perhaps blocks substrate 
access to site 1. Ubiquitin binds at site 2, and either induces or stabilizes the open state. This 
allows the substrate to bind at site 1, after which it is cleaved by the active site Cys residue (red), 
and released. 
 
We find that the Josephin site 2 and the UIMs both contribute to the stimulation of activity, 
suggesting a cooperative effect. Collaboration between the UIMs and the Josephin has already 
been demonstrated in substrate selectivity (117); it is perfectly reasonable that their coordination 
is extended to scenarios involving non-covalent interactions and conformational changes within 
the enzyme. First, the freely accessible UIMs would selectively bind K63- or mixed-linkage chains 
with high affinity (34,117). The UIMs themselves exhibit cooperativity and preferentially bind 
polyubiquitin substrates of four or more subunits in vitro (34). Once a chain of appropriate length 
is trapped, it could migrate until it encounters and binds the Josephin, via cooperative interactions 
involving all the binding sites (Fig. 3.8A). Alternately, occupancy of the UIMs may transduce an 
allosteric signal to the Josephin, stimulating a catalytically enhanced conformation at the active 
site (Fig. 3.8B). It is also possible that the unstructured C-terminus partially occludes the Josephin 
sites (259), and that binding of ubiquitin to the UIMs exposes these sites (Fig. 3.8C). Once ubiquitin 
interacts with the Josephin and is properly positioned for cleavage, it can be hydrolyzed at the 
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DUB active site, after which it must be released. The ubiquitin chain may be released via 
competitive interactions with Rad23 that also binds to site 2 (102). Alternately, when the chain is 
trimmed to less than four moieties, it may simply detach due to low affinity binding. This 
exemplifies ataxin3 as a polyubiquitin specific “molecular ruler” that selects and trims chains to 
an appropriate length, via its multiple binding sites. Indeed, the DUB effectively cleaves chains 
comprising more than five ubiquitins to produce tetra-ubiquitin (117,118), which correlates with 




Figure 3.8 Models for coordination between the UIMs and the Josephin domain. The 
Josephin domain is shown in orange, the flexible C-terminal and UIMs in brown, and the ubiquitin 
molecules are shown as teal spheres. A, the UIMs first trap a poly-ubiquitin chain, which can then 
migrate until it encounters and binds the Josephin. B, the UIMs bind ubiquitin, and transduce the 
bound signal to the Josephin, which induces a catalytically enhanced conformation at the active 
site. C, the unstructured C-terminus partially occludes the Josephin sites, and binding of ubiquitin 
to the UIMs exposes these sites. 
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The first insight into interpreting ubiquitin signals came from the identification of the Leu-
8/Ile-44/Val-70 hydrophobic patch on ubiquitin, which is necessary for its interaction with the 
S5a/Rpn10 proteasomal subunit (260). The same patch, along with another hydrophobic surface 
on ubiquitin, mediates vegetative growth and endocytic transport in yeast (261). Thus, the surface 
of a ubiquitin molecule is essentially made up of three-dimensional signals that are read by 
distinct sites or domains (e.g. the UBD) on proteins. A polyubiquitin chain would present 
hydrophobic surfaces from each ubiquitin moiety to such a binding domain, enabling a 
multivalent interaction. Non-covalent interactions involving hydrophobic interfaces are 
important in a biological context, since low affinity and transient binding would ensure that the 
interaction is readily reversible. This may be necessary to proceed to the next phase in a pathway 
(e.g. release of the substrate after proteasomal recognition, to facilitate its degradation), or to 
reversibly regulate enzymes that function in ubiquitin pathways (e.g. to activate DUBs when 
required, and to deactivate them later, thus preventing indiscriminate proteolysis). 
Our results show that non-covalent ubiquitin interactions directly regulate ataxin3’s 
enzymatic properties, and thus define a novel, non-traditional role for the signaling molecule. 
This mode of control by ubiquitin may also apply to other DUBs, further refining their cellular 
functions. It makes biological sense that DUB activity would be modulated through allosteric 
interactions with their substrates, and essentially be “turned on” when the substrate needs to be 
cleaved. In this way, during cellular stress, the high levels of ubiquitinated substrates that require 
processing would themselves upregulate DUB activity. 
  
 78 
CHAPTER 4: Conclusions 
 
4.1. Nucleotide-induced conformational changes regulate the p97-ataxin3 interaction 
4.1.1. Summary 
A remarkable aspect of p97 is its involvement in diverse cellular processes. Over the last 
decade, it has become clear that p97 achieves its functional diversity by employing a multitude of 
cofactors. These cofactors partner with p97 in unique and sometimes interdependent ways, 
reflecting their distinct roles in p97 function, and thus giving rise to a complex network of p97-
cofactor interactions. Cofactors follow a hierarchy in their binding to p97 (63). Much of the binding 
mechanism is dictated by the stoichiometry and spatial arrangement of the complex. Our EM 
analyses of full-length proteins clearly demonstrate that only one ataxin3 molecule binds to the 
p97 hexamer, which leaves room for other cofactors. Alternately, the binding of ataxin3 could also 
prevent interaction with other cofactors. This idea is strongly supported by experiments showing 
mutually exclusive binding of ataxin3 and Ufd1 to p97 (37). It is unclear whether the binding of a 
single cofactor to p97 can induce a conformational change to rearrange the other N-domains, but 
such a mechanism would explain the diverse cofactor-binding patterns observed. In this case, a 
1:6 ataxin3-p97 complex could certainly A) inhibit additional ataxin3 binding, and B) selectively 
promote or inhibit interaction with other cofactors.  
Many of the p97 cofactors have antagonistic functions, which may be required at different 
instances within a pathway, and would eventually decide the fate of the substrate. Thus, cofactor 
binding must be carefully regulated. Regulation occurs in various ways, including post-
translational modification (65,214) and transcriptional upregulation of cofactors (262,263). Our 
experiments reveal that in the case of ataxin3, binding is regulated by p97’s nucleotide state. High 
resolution cryo-EM has revealed at least three distinct nucleotide-bound conformations that 
clearly place the N-domain in different positions relative to the D1 ring (43). ADP-bound p97, 
with the N-domains in the down state, does not interact with ataxin3 due to steric constraints, as 
the C-terminus of ataxin3 clashes with the D1-domain. However, interaction is restored in the 
ATP-bound or nucleotide-free states, where the N-domains are in the up position. These results 
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recapitulate cellular studies showing differential binding of ataxin3 to p97 in the presence of 
different nucleotides (113). Thus, ataxin3 may shuttle on and off p97, perhaps to facilitate the 
association of other cofactors required for processing substrates.  
In addition to cofactor studies of the wild type, there are also reports characterizing MSP1 
mutants of p97, and their atypical cofactor binding; however, these studies have not focused on 
nucleotide regulation. None of the identified MSP1 mutations are in p97’s nucleotide-binding sites 
or cofactor interfaces, so their effects on cofactor binding are most likely indirect and subtle. 
Consequently, cofactor-binding experiments must be interpreted with caution. Studies using 
purified proteins are often inconsistent with cell-based experiments, and do not recapitulate the 
differences in cofactor-binding ability observed between wild type p97 and MSP1 variants 
(53,89,91); such discrepancies may be resolved by accounting for p97’s nucleotide state. Our 
results have shown that although ataxin3 binds to wild type and mutant p97 with the same 
affinity, ADP does not inhibit its interaction with the mutants; this explains the elevated binding 
of mutant p97 with ataxin3 observed in cultured cells, and in patient tissue samples (53). Our 
findings are consistent with defective inter-domain communication in MSP1 mutants, explained 
as the inability of these mutants to transduce the ADP-bound signal from the D1 to the N-domain. 
This disrupted up-down equilibrium may also alter the binding of other cofactors, with potential 
consequences in protein quality-control pathways. 
The p97-ataxin3 interaction is an essential component of ERAD (37,38), where p97’s primary 
function is to extract ubiquitinated substrates from the ER; however, the precise mechanism of 
this process remains unclear. Conceivably, ataxin3 binds and catalyzes the trimming or the en bloc 
removal of ubiquitin chains substrates that would otherwise sterically impede their engagement 
or threading by p97. A similar processive function is observed in the proteasome-associated DUB 
Rpn11, which facilitates substrate entry into the proteasome (264). Another possibility is that 
ataxin3 edits non-K48 linked polyubiquitin that will not be efficiently recognized by the 
proteasome; this is consistent with the DUB’s preference for long, mixed-linkage chains as 
substrates (117). Ataxin3 may also trim excessively long ubiquitin chains downstream of 
extraction to an appropriate length necessary for proteasomal degradation, before substrate hand-
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off to shuttling factors like Rad23 and Dsk2 (217,218). Besides coordinating substrate extraction, 
ataxin3 may further assist p97 in engaging ubiquitinated substrates. The DUB binds ubiquitin via 
sites on its Josephin domain and its UIMs (33,34,119), and p97 also has a predicted polyubiquitin 
recognition site on its N-domain, adjacent to the ataxin3-binding cleft (57,157). The spatial 
arrangement of these sites may facilitate the simultaneous interaction of the polyubiquitinated 
substrate with both ataxin3 and p97, and thereby synergistically enhance the relative binding 
affinities of these interactions. Moreover, our EM studies with non-crosslinked proteins hint at the 
possibility of a flexible association between ataxin3 and p97. It is tempting to imagine a scenario 
where ataxin3 is attached to p97 by its C-terminal VBM, leaving the Josephin domain and UIMs 
free to move about and bind longer ubiquitin-chains. Besides ataxin3, other DUBs like Otu1, 
VCIP135 and YOD1 function with p97, both in yeast and mammalian cells (262,265-267), 
indicating an evolutionary role for DUBs in p97-dependent processes. 
In vivo, even minor errors in cofactor interactions could be toxic. p97 may become trapped in 
ineffective complexes unable to bind other cofactors, and thus disrupt degradation pathways, 
causing ubiquitinated proteins to be shuttled off to autophagic vacuoles. A pathological hallmark 
of MSP1 is the co-localization of mutant p97 with ubiquitinated protein inclusions, indicative of a 
defective UPS (82,83). Disrupted autophagosomes and endosome maturation is also observed, 
which leads to vacuolation, weakness and muscle atrophy (86,87). It is conceivable that mutants 
alter the normal equilibrium between shuttling to the proteasome and autophagy. Atypical 
cofactor binding has also been observed in MSP1 patient myoblasts that lack protein aggregates 
(53,89), implying that this is an early event in pathogenesis rather than a consequence of the 
disease. We propose that MSP1 mutations cause subtle but ultimately fatal errors in p97 function, 
which is consistent with a late-onset disease. Our findings that p97 mutants do not necessarily 
abolish, but alter cofactor-binding patterns via dysregulated N-domain conformations, validate 
the complex nature of these interactions and support the proposed pathogenesis mechanism. 
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4.1.2. Future directions 
A) We have shown that ADP binding to p97 inhibits its interaction with ataxin3. The mechanism 
is through the downward displacement of the p97 N-domain in the ADP-bound state that 
results in a steric clash between the D1 domain and the ataxin3 C-terminal. It would be 
interesting to examine the interaction of other cofactors in the light of p97 nucleotide states. If 
nucleotides regulate the binding of other cofactors to p97, we could investigate if this was 
through a similar mechanism as that observed for ataxin3. Analyses of published p97-cofactor 
complex structures (complete list in Appendix 2 supplemental Table 3), would help establish 
rationale for testing cofactors whose interactions with p97 are likely to be inhibited in the 
down state. For example, the UBL from Otu1 and the UBD from Npl4 both bind in the p97 N-
domain inter-lobe cleft (44,58). The UBL and UBD domains are located at the N-terminal 
halves of their respective proteins. Conceivably, the C-terminal portions of these proteins may 
be positioned such that they clash with the D1 in the ADP-bound form of p97. The opposite 
orientation may produce the same effect in the case of the UBX domain from p47 (56), another 
cofactor that exhibits reduced binding to p97 in the presence of ADP (66).  
B) We could also test the binding of other cofactors to p97 MSP1 mutants in the presence of 
nucleotides. Since the up-down equilibrium of the N-domain is altered in disease mutants, it 
is possible that atypical cofactor binding will only be detected in the context of p97’s 
nucleotide state. In our experiments, ataxin3 binding to p97 mutants was not inhibited by 
ADP. Such altered ADP-inhibition has also been reported for the binding of p47 to mutant 
p97 (66).  
C) Some cofactors like p37 and p47 play critical roles in regulating p97’s ATPase activity. p37 
produces an 11-fold increase in catalytic efficiency, and was the first activating cofactor to be 
identified. p47 shows a more complex regulation profile that is dependent on its 
concentration. These cofactors control ATPase activity by binding to p97’s N-domain, thereby 
inducing conformation changes in the protein that affect nucleotide binding at the D1 (67). 
Since ataxin3 binds in the same N-domain cleft, and the interaction is regulated by nucleotide-
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induced conformational changes, we decided to investigate the effect of ataxin3 on p97 
activity. Preliminary experiments show that wild type ataxin3 stimulates ATP hydrolysis, 
while the VBM mutant that does not interact with p97 has no effect at the same concentrations 
(Appendix 1). These initial results necessitate a more in-depth kinetic analysis of the observed 
stimulation, over a wider range of ataxin3 concentrations. Also, it is unlikely that this effect 
can be explained by the same rationale postulated for p37 and p47, since the binding of ataxin3 
to the N-domain is not strong enough to affect nucleotide binding; in fact, nucleotide binding 
inhibits the interaction. So ataxin3 likely enhances ATPase activity by some other mechanism. 
Moreover, p37 and p47 failed to activate p97 disease mutants (67). Since mutants typically 
exhibit increased activity, and the p97-ataxin3 interaction is altered in these mutants, it would 
be interesting to test if ataxin3 effects ATP hydrolysis in the mutants. 
 
 
4.2. Ataxin3 is activated by non-covalent interactions with ubiquitin 
4.2.1. Summary 
The cellular functions of DUBs are regulated through a combination of specific protein-
protein interactions, modulatory domains, and post-translational modifications. DUBs comprise 
various binding motifs, and interact with distinct partners that target them to specific pathways, 
confer substrate preferences, and modulate enzyme activity. We have shown that the DUB activity 
of full-length ataxin3 is stimulated by non-covalent interactions with Ub and UbHis6, and that 
these low-affinity interactions are able to induce a 3-fold and a 50-fold increase in the rate of 
substrate hydrolysis, respectively. The ubiquitin constructs also induce a smaller, yet significant, 
stimulation of DUB activity in the isolated Josephin domain. Moreover, we have shown that this 
stimulation is through an additive effect of both the Josephin site 2 and the UIMs.  
The enhancement of ataxin3 activity through ubiquitin interactions may constitute a feed-
forward regulatory process in various cellular pathways. We suggest that regulation of enzymatic 
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activity by non-covalent substrate interactions would further refine the cellular functions of DUBs, 
and that binding of ubiquitin may also stimulate activity in other classes of enzymes. 
 
4.2.2. Future directions 
A) The Josephin domain of ataxin3 interacts with the N-terminal UBL domain of the proteasome-
associated shuttling factor Rad23B (102). The Rad23B binding site overlaps with Josephin site 
2, in fact, the W87K mutation that abrogates ubiquitin binding at site 2, also disrupts the 
Rad23B interaction (135). Since Ub and UbHis6 stimulate ataxin3 activity via site 2, we could 
test the effect of Rad23B on DUB activity, at similar concentrations. We could also test if 
Rad23B competes for the site, and perhaps inhibits the stimulation by UbHis6. Previously, 
full-length Rad23B was shown to reduce the ability of the Josephin domain to cleave poly-
ubiquitin chains (118). Competition experiments may help define a mechanism for this form 
of inhibition. 
B) We could test if other ubiquitin conjugates also stimulate the rate of substrate cleavage. For 
example, K48- and K63-linked di-ubiquitin are both substrates of ataxin3, and are cleaved 
with a similar efficiency as that observed for UbHis6. We would use di-ubiquitin at the same 
concentration as UbHis6 and check for stimulation of activity. This would also verify whether 
the stimulation is due to the substrate-like property of UbHis6, or just an artifact of the His6-
tag. We could also test for stimulation in the presence of poly-ubiquitin chains with K48-, K63-
, and mixed-linkages. Additionally, we could test a fusion protein comprising multiple 
ubiquitin moieties, linked via regular peptide bonds instead of the isopeptide linkage in 
chains. This would be a poorer substrate than regular chains, and would not compete 
significantly with the assay substrate. We would also vary the number of ubiquitin moieties 
in this fusion construct to test the effect of chain length on stimulation of activity.  
C) To detect any structural changes in ataxin3, due to the binding of Ub and UbHis6, we would 
perform intrinsic fluorescence measurements for ataxin3, in the presence and absence of Ub 
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and UbHis6. The signal from the ubiquitin constructs should be negligible since they do not 
contain any Trp residues.  
D) Our studies with Ub and UbHis6 were performed at fixed concentrations of these ubiquitin 
constructs (see section 3.2.4 for experimental conditions). We would next test the 
concentration dependence of DUB stimulation, using a range of Ub and UbHis6 
concentrations, and verify if it correlates with reported ubiquitin binding affinities. We could 
also test the kinetics of DUB activity, and verify if the relation between the rate of cleavage 







APPENDIX 1: Ataxin3 Stimulates p97 ATPase Activity. 
 
Some p97 cofactors like p37 and p47 play critical roles in regulating its ATPase activity. p37 
stimulates p97’s ATPase activity, and p47 shows a more complex regulation profile that is 
dependent on its concentration. These cofactors control ATPase activity by binding to p97’s N-
domain, thereby inducing conformation changes in the protein that affect nucleotide binding at 
the D1 (67). Since ataxin3 binds in the same inter-lobe cleft, we decided to investigate the effect of 
ataxin3 on p97 activity.  
Using the NADH-coupled assay (see section 2.2.7) we measured the ATPase activity of p97 
(at 0.5 µM monomer) in the absence and presence of an increasing concentration of wild-type 
ataxin3 (0–20 µM). Ataxin3 stimulated p97’s activity in a concentration dependent manner, with 
an approximately 2.5-fold stimulation at the highest concentration tested (20 µM ataxin3; this 
corresponds to a molar ratio of 1:40 for the p97 monomer : ataxin3). (Appendix 1 Fig. 1). In 
comparison, Zhang et al. showed that p37 produces a 3.7-fold stimulation of ATPase activity at 
molar ratio of 1:20 (p97 monomer : p37) (67). We next tested if the VBM mutant that does not 
interact with p97 produces any stimulation at the two highest concentrations of wild-type tested, 
and found that addition of the mutant does not change p97 activity (Appendix 1 Fig. 2). These, 
preliminary experiments show that wild-type ataxin3 stimulates ATP hydrolysis, while the VBM 




Appendix 1 Figure 1. Ataxin3 stimulates p97 activity. Graph showing the relative increase in 
p97 ATPase activity with increasing concentrations of ataxin3 (0–20 µM). (n = 3 for each reaction) 





Appendix 1 Figure 2. The VBM mutant does not stimulate p97 activity. Graph showing relative 
increase in p97 ATPase activity with the last two concentrations of ataxin3, and no increase with 
the VBM mutant at the same concentrations (n = 3 for each reaction). Ataxin3 WT and MT 





APPENDIX 2: Supplemental Protocols, Tables and Figures for Chapter 2. 
 
 
Appendix 2 Supplemental Protocols 
1. Protein Expression and Purification 
All proteins were expressed in E. coli Rosetta (DE3) cells (Novagen), by induction with 1 mM 
isopropyl-b-D-thiogalactopyranoside (IPTG) at an A600 of 0.5–0.8, followed by shaking overnight 
at 24 °C. After roughly 21 h, the cells were harvested by centrifugation at 5,000 × g and the pellets 
were resuspended in water and flash-frozen. Attempts were made to express the p97 N-domain 
in E. coli Rosetta (DE3) cells using an auto-induction protocol (243), but this resulted in a large 
amount of the protein being in the pellet after the centrifugation steps, indicating denatured or 
aggregated protein; this was not observed when using the IPTG induction protocol. Preceding 
purification, the pellets were rapidly thawed under running water and resuspended in lysis 
buffer. All cells were lysed by at least two passes through a chilled Emulsiflex-C5 homogenizer 
(Avestin, Ontario, Canada) at approximately 173 MPa. For the His6-SUMO-fusions, lysis, 
clarification and subtractive purification were performed as described previously (198), expect for 
minor changes described below.  
For all the His6-SUMO-ataxin3 constructs (full-length wild-type, full-length 282ANAA285 
mutant, Josephin domain, Josephin + UIMs, ataxin3ΔC and ataxin3ΔN), the cells were lysed in 50 
mM sodium phosphate, pH 8.0, 250 mM NaCl, 20 mM imidazole, 10 mM MgCl2, 5 mM β-
mercaptoethanol (βME), 5% v/v glycerol, 1 µg/ml each DNAse and RNAse, and protease inhibitor 
(Prod. #88266, Pierce ThermoFisher; 1 tablet/ 50 ml lysate). The lysates were clarified at 311,000 × 
g for 1 h and loaded onto a HiTrap IMAC HP column pre-equilibrated with 50 mM sodium 
phosphate, pH 8.0, 250 mM NaCl, 20 mM imidazole, 5% v/v glycerol, 5 mM βME, and eluted using 
a 20–300 mM gradient of imidazole. The eluted fractions were pooled and dialyzed back into 50 
mM sodium phosphate, pH 8.0, 250 mM NaCl, 20 mM imidazole, 5% v/v glycerol, 5 mM βME, at 4 
°C, in the presence of the doubly-tagged SUMO-specific protease Ud1 (dtUd1) (198). 200 µg of 
protease is sufficient to cleave the amount of fusion protein obtained from a 1-L culture. After an 
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overnight dialysis, the sample was applied to the same metal affinity chromatography column to 
remove the His6-SUMO tag and the dtUD1 enzyme. After subtractive purification, the ataxin3 
constructs were further purified by ion exchange chromatography. The proteins were first 
dialyzed against 50 mM sodium phosphate, pH 8.0, 50 mM NaCl, then loaded onto a HiTrap 
Sepharose Q HP column and eluted using a 50–1000 mM gradient of NaCl. The desired fractions 
were pooled and further purified by size-exclusion chromatography (SEC) on a HiPrep Sephacryl 
S-300 HR column equilibrated in 25 mM Tris, pH 8.0, 200 mM KCl, 5 mM MgCl2, 5 mM βME. For 
the N-terminally His6-tagged ataxin3 protein, the Ud1 cleavage and subtractive purification steps 
were omitted. 
For all the His6-SUMO-p97 constructs (full-length wild-type protein, with and without the 
C-terminal 1D4-tag, p97 N-domain, p97N + D1-domains, and all p97 mutants), the cell pellets 
were lysed in in 50 mM Tris, pH 8.0, 250 mM KCl, 20 mM imidazole, 10 mM MgCl2, 5 mM βME, 5% 
v/v glycerol, 1 µg/ml each DNAse and RNAse, and protease inhibitor tablets (details above). 
Clarification and subtractive purification were performed as described for the ataxin3 constructs, 
except the IMAC buffer contained 50 mM Tris, pH 8.0, 250 mM KCl, 20 mM imidazole, 5 mM MgCl2, 
5 mM βME, 5% v/v glycerol, and the elution was over a 20–300 mM gradient of imidazole. After 
subtractive purification, the proteins were directly purified by gel filtration as described above. 
For the ITC experiments, full-length p97 was subjected to an additional ion exchange 
chromatography step before SEC, through a HiTrap Sepharose Q HP column, using a buffer with 
100 mM HEPES, pH 7.0, 50 mM NaCl, 5 mM βME, and a 50–500 mM linear NaCl gradient. This step 
was to ensure the removal of any aggregated material in order to concentrate full-length p97 
sufficiently for ITC. The C-terminally His6-tagged full-length p97 was expressed as a SUMO-
fusion, which helped in expression and solubility. The SUMO was later removed by cleavage with 
dtUd1 as described above, and the sample was purified by gel filtration. On our preparative 
Sephacryl S-300 column, the elution profile for full-length p97 was similar to that described by 
Niwa et al. (54) using a Superose 6 column (supplemental Fig. S11A). Niwa et al. verified that their 
void peak contained irreversibly aggregated material, and the additional shoulder present in their 
trace contained dodecameric p97 with some aggregates. To further analyze the size-exclusion 
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behavior of p97, we injected full-length p97 onto a Yarra SEC-3000 column (for improved 
separation of high molecular-weight species), and observed a smaller peak between the void peak 
and hexamer peak (supplemental Fig. S11B). This peak most likely contained higher-order 
oligomers and/or aggregates, and was in equilibrium with the hexamer species, since reinjection 
of the hexamer peak yielded the same three-peak elution profile (data not shown). 
For all ataxin3 and p97 proteins, the final SEC fractions from the Sephacryl S-300 column 
were pooled and concentrated to 8–10 mg/ml using an Amicon stirred cell (Millipore), and then 
aliquoted, flash-frozen, and stored at –80 °C. 
 
2. Surface Plasmon Resonance (SPR) 
All SPR experiments were performed on a BioRad ProteOn XPR36 at 25 °C. The full-length 
p97 hexamer was captured as a ligand in an oriented manner employing two different strategies, 
A) the Rho1D4 epitope-antibody system (200,201) and B) histidine-tagged protein capture. 
Rho1D4 epitope-antibody system. The Rho1D4 monoclonal antibody was immobilized on a 
ProteOn GLC sensor chip by amine coupling using 1× PBS pH 7.4 plus 0.005% Tween® 20 as the 
running buffer. The surface was first activated with a freshly prepared mixture of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide 
(sulpho-NHS), (final concentrations 20 mM EDC : 5 mM sulpho-NHS), at a flow rate of 30 µl/min 
for 5 min. The 1D4 antibody was diluted in 10 mM sodium acetate, pH 5.5 (final concentration 0.1–
0.5 mg/ml), and immobilized to a density of ~3,500 response units (RU) on the activated surface, 
at a flow rate of 30 µl/min for 7 min. Excess activated groups were blocked with 1 M ethanolamine-
HCl, pH 8.5 at a flow rate of 30 µl/min for 5 min. The surface was stabilized by at least three 
consecutive injections of regeneration solution (freshly prepared 10 mM NaOH and 1% N-octyl-
β-D-glucopyranoside), each at a flow rate of 100 µl/min for 18 s. For each sensor chip, one of the 
lanes with the immobilized 1D4 antibody was maintained as the reference surface. The buffer was 
switched to 25 mM Tris, pH 8.0, 200 mM KCl, 5 mM MgCl2, 0.1 mM TCEP, 0.005% Tween® 20. C-
terminally 1D4-tagged full-length p97 and p97 mutants were diluted into this buffer (final 
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concentration 5–50 µg/ml) and captured (100–150 RU) as ligands on the antibody-coated surfaces, 
at a flow rate of 50 µl/min for 30 s. Various concentrations of analytes, including ataxin3, the 
282ANAA285 mutant, and fragments with and without nucleotides, were diluted in the Tris 
buffer and passed over the chip at 150 µl/min, for the maximum possible contact time of 163 s. 
Some experiments involving the p97 R155C/N387C variant also included either 7 mM DTT or no 
reducing agent, instead of TCEP, as indicated in the main text and figures. The surface was 
regenerated completely with three injections of freshly prepared regeneration solution, at 100 
µl/min for 18 s, before the next round of 1D4-tagged ligand capture.  
His6-tagged protein capture. The ProteOn HTG sensor chip surface was first activated with 10 
mM NiSO4 (30 µl/min for 120 s) following the standard protocol recommended by the 
manufacturer. C-terminally His6-tagged full-length p97 hexamer (final concentration 0.1–0.4 
mg/ml) was captured on the chip to a density of 200–300 RU, using a flow rate of 30 µl/min for 
120 s. A reference surface was generated for each chip using His6-tagged MBP as a control protein. 
Full-length ataxin3 was flowed over as the analyte, at the concentrations indicated (supplemental 
Fig. S1), at 100 µl/min, for a contact time of 200 s. Running and dilution buffers used throughout 
contained 25 mM Tris, pH 8.0, 200 mM KCl, 5 mM MgCl2, 1 mM βME, 5% v/v glycerol, and 0.005% 
Tween® 20, and the surface was regenerated with three injections of 300 mM EDTA, pH 8.5, at 30 
µl/min for 800 s, before the next round of His6-tagged p97 capture. We observed that a small 
amount of the ligand accumulated on the chip with each subsequent round of capture, 
presumably via non-specific aggregation, and the regeneration steps were thus unable to 
completely clear this material. However, reproducible results were obtained over as many as six 
rounds of p97-His6 capture for each flow strip.  
The p97 N-domain was immobilized as the ligand on a ProteOn GLC sensor chip by amine 
coupling, using the same protocol described above. 1D4-tagged N-domain was not used for SPR 
experiments, as baselines obtained with this construct displayed significant drift. The p97 N-
domain was diluted in 10 mM sodium acetate, pH 5.0 (final concentration 20 µg/ml), and directly 
immobilized on an activated chip to a density of 400–500 RU, at 30 µl/min for 7 min. The chip was 
blocked with 1 M ethanolamine-HCl, pH 8.5 as described above and stabilized with at least three 
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injections of running buffer (30 µl/min for 1 min). The running and dilution buffers used for all 
p97 N-domain experiments contained 1× PBS, pH 7.4, and 0.005% Tween® 20. A reference surface 
was generated for each chip using the 1D4 antibody immobilized to the corresponding density. 
Full-length ataxin3 was flowed over as the analyte at the concentrations indicated (Fig. 2B), at 150 
µl/min for a contact time of 163 s. 
All binding data were first double-referenced to the control flow strip with immobilized 
Rho1D4 antibody alone, as well as buffer injections during the analyte step. The data were then 
normalized, relative to the total ligand density on the corresponding surface (Eq. 1), to account 
for minor differences in ligand immobilization between experiments.  
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The processed data were fit to an equilibrium binding model using GraphPad Prism 7.0 to 
derive the binding affinity. A global 1:1 kinetic analysis of the binding data resulted in poor fits, 
especially at lower concentrations (supplemental Fig. S12). This deviation from ideal first-order 
binding kinetics may reflect the need for a more complex interaction model, or, alternatively, 
might indicate surface-induced artifacts. Since we had no substantial evidence to support a more 
complex interaction scheme (e.g., conformational changes occurring upon analyte binding or 
multiple binding sites), we probed the data for mass-transport effects and rebinding events, and 
optimized conditions to minimize these artifacts, following strategies recommended in (268). We 
first compared the initial association signals obtained by exposing analyte to different densities of 
the immobilized ligand (supplemental Fig. S13A). The analyte responses, when normalized to the 
total corresponding ligand density on that surface, produced superimposable curves across flow 
strips with densities < 200 RU. Ligand densities greater than 200 RU showed slower association 
kinetics, indicating the presence of mass transport artifacts (supplemental Fig. S13A). Thus, we 
ensured that p97-1D4 was captured to densities of 100–150 RU for all experiments; this level is 
low enough to minimize mass-transport effects and yet sufficiently high to maintain a good 
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signal/noise ratio. Additionally, a high flow rate of 150 µl/min was used for the analyte, since we 
detected increased mass-transport effects using lower flow rates (data not shown). We also tested 
for rebinding events by introducing a competitor in the dissociation phase (excess untagged p97); 
by binding to the dissociated analyte, this competitor will prevent rebinding to the immobilized 
ligand. A significantly faster dissociation was observed in the presence of the competitor 
(supplemental Fig. S13B), indicating that the system was mass-transport limited and that the true 
dissociation rate was probably greater than the observed rate. Based on these findings, we 
concluded that kinetic analyses were untrustworthy in this system, and therefore we limited our 
data analysis to derivations of binding affinity from equilibrium measurements, which are 




Appendix 2 Tables  
 
Appendix 2 Table 1. Equilibrium dissociation constant (KD) values for the interaction between 















a Values were calculated using the equilibrium binding response from 3 or more SPR experiments 
for each interacting pair. Data were fit to a one-site specific binding model using GraphPad Prism 
7.0 
b Values were calculated from 3 or more ITC experiments for each interacting pair. Data were fit 







Full-length (1–806) Full-length (1–345) 3.7 ± 0.9a ; 8.4 ± 0.1b 
Full-length (1–806) Ataxin3ΔC (1–292) 4.3 ± 0.6a 
p97 N-domain (1–187) Full-length (1–345) 6.4 ± 1.5a ; 4.5 ± 0.2b 
p97 N-domain (1–187) Ataxin3ΔC (1–292) 2.8 ± 0.1b 
p97 N-domain (1–187) Ataxin3ΔN (220–345) 4.0 ± 0.4b 
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Appendix 2 Supplemental Table 1. Expression constructs and primers used in this work. 
Plasmids pETHSUL and pETCH have been described elsewhere (198). For all the His6-SUMO-
fusions, a single Gly residue was inserted between the protease cleavage site and the N-terminus 
of each protein, to increase the efficiency of cleavage by the SUMO-specific protease Ud1.  
 


























































































Abbreviations: Ligation independent cloning (LIC), p97 N- and D1- domains (p97 ND1) and 
Ubiquitin interacting motifs (UIMs).   
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Appendix 2 Supplemental Table 2. Primers used for one-step site-directed mutagenesis of 









Y143A 1: CTGGAAGCGGCTCGACCCATCCGGAAAGGAGACATTTTTCTTGTCCG 2: GGTCGAGCCGCTTCCAGGAAGTACGGCTTAAGGTATACCTCGAAGAG 
L72A 1: CATCGTCGCTTCTGATGATACTTGTTCTGATGAGAAGATTCGGATGAATAGAG 2: CATCAGAAGCGACGATGCAAACAGCTTCTCGTCTCTTCTTTCCTTTCAGC 
R53A 1: GTTGTTCGCAGGTGACACAGTGTTGCTGAAAGGAAAGAAGAGACGAGAAGCTG 2: GTGTCACCTGCGAACAACTGCAATTCATCCATCTTGGGCTGGGACAAG 
G54W 1: GTTCCGATGGGACACAGTGTTGCTGAAAGGAAAGAAGAGACGAGAAG 2: CTGTGTCCCATCGGAACAACTGCAATTCATCCATCTTGGGCTGGG 
K251A 1: GAACAGGAGCTACCCTGATTGCTCGAGCTGTAGCAAATGAGACTGGAG 2: ATCAGGGTAGCTCCTGTTCCAGGAGGTCCGTAAAGCAGGATTCCTC 
K524A 1: CTGTGGGGCTACTTTGTTGGCCAAAGCCATTGCTAATGAATGCCAG 2: CAACAAAGTAGCCCCACAGCCAGGAGGTCCATAGAACAGAACTCCC 
K251A/K524A K251A and K524A were used together 
R155C/N387C 
R155C 1: TTTTCTTGTCTGCGGTGGGATGCGTGCTGTGGAGTTCAAAGTGGTGG 
            2: CCACCGCAGACAAGAAAAATGTCTCCTTTCCGGATGGGTCGATACG 
N387C 1: AAGTGCATGAAGCTGGCAGATGATGTGGACCTGGAACAGGTAGCCAATG 
            2: CTGCCAGCTTCATGCACTTGGTATGGATCTGAAGAATCTCTAAGCGTCC 
R155H 1: TTTTCTTGTCCATGGTGGGATGCGTGCTGTGGAGTTCAAAGTGGTGG 2: CCACCATGGACAAGAAAAATGTCTCCTTTCCGGATGGGTCGATACG 
L198W 1: AGAGTCCTGGAATGAAGTAGGGTATGATGACATTGGTGGCTGCAGG 2: ACTTCATTCCAGGACTCTTCCTCATCCTCTCGTTTGATAGGCTCCC 
A232E 1: CCCTCTTTAAGGAAATTGGTGTGAAGCCTCCTAGAGGAATCCTGC 2: CCAATTTCCTTAAAGAGGGCAGGATGTCTCAGGGGCAGTTCCAC 
L198W/R155C 
/N387C 
L198W primers were used with the pETHSUL-R155C/N387C mutant 
A232E/R155C 
/N387C 

















N Ufd1 peptide 221 µM ITC SHP box 5B6C (269) 
N Npl4 ULD 17.8 µM ITC ULD 2PJH (44,270) 
FL p97 FL Ufd1/Npl4 1.7 µM ITC SHP box / 
ULD  (63) ND1 FL Ufd1/Npl4 2.1 µM ITC 




FL p97 FL p47 0.7 µM ITC 
UBX / SHP 
box 1S3S (56,63,66) 
ND1 FL p47 0.54 µM ITC 
FL p97 FL p47 
22 nM, 0.89 
µM SPR 
FL p97 FL p37 19 nM SPR UBX  (66) 




N Faf1 UBX 25.6 µM ITC 
ND1 FL SVIP 0.67 µM ITC 
VIM  (64,161) NL FL SVIP 5.92 µM ITC 
N SVIP peptide 6.6 µM ITC 
ND1 gp78 peptide 21.3 nM BLI 
VIM 3TIW (64,161) 
N gp78 peptide 5 µM ITC 
ND1 
ANKZF1 
peptide 16.3 nM BLI VIM  (64) 
FL p97 FL UBXD1 3.5 µM ITC VIM / PUB  (64) 
N 
RHBL4 C-
terminal 68.9 µM SPR VBM 5EPP (206) 
N Hrd1 peptide 47.8 µM ITC VBM  (161) 









FL p97 FL Ataxin3 
3.7 ± 0.9 
µM 
SPR 
N FL Ataxin3 
6.4 ± 1.5 
µM 
SPR 
N FL Ataxin3 
4.5 ± 0.2 
µM 
ITC 
Abbreviations: Full-length (FL), p97 N- and D1- domains (ND1), p97 N-domain (N), Ubiquitin-fusion 
degradation protein 1 (Ufd1), Nuclear localization protein 4 (Npl4), Ovarian tumor domain-containing 
protein 1 (Otu1), Fas-associated factor 1 (Faf1), Small valosin-interacting protein (SVIP), Ankyrin repeat and 
zinc finger domain-containing protein 1 (ANKZF1), Ubiquitin regulatory X domain protein 1 (UBXD1), 
Rhomboid protease (RHBDL4), HMG-CoA reductase degradation protein 1 (Hrd1), Isothermal Titration 
Calorimetry (ITC), Surface plasmon resonance (SPR), Biolayer interferometry (BLI), Ubiquitin-like domain 
(ULD, also known as UBD), Ubiquitin regulatory X domain (UBX), UBX-like domain (UBL), peptide:N-
glycanase/ UBA or UBX (PUB), p97/VCP-interacting motif (VIM), and p97/VCP-binding motif (VBM).  
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Appendix 2 Supplemental Figure S1. Alternate p97 preparations have the same affinity for 
ataxin3. (A) Representative sensorgram for full-length ataxin3 binding to full-length p97-His6 
(ataxin3 concentrations 0–20 µM, n ≥ 3 for each concentration). (B) Normalized equilibrium 
response fit of the data in A to a one-site binding curve (KD = 2.2 ± 0.2 µM). (C) Representative 
sensorgram for full-length ataxin3 binding to full-length p97-1D4 (ataxin3 concentrations 0–100 
µM, n ≥ 3 for each concentration). The p97-1D4 sample was purified using an additional ion 
exchange chromatography step, similar to the ITC sample preparation. (D) Normalized 
equilibrium response fit of the data in C to a one-site binding curve (KD = 2.4 ± 0.2 µM). The 











Appendix 2 Supplemental Figure S2. Negative-stain electron microscopy (EM) analyses of 
the p97-ataxin3 complex. (A) Left, electron micrograph showing negatively-stained hexamers 
of p97 bound to ataxin3 (non-crosslinked). The magenta box highlights one p97-ataxin3 
complex. Right, raw images of the complex viewed down the 6-fold axis, shown at higher 
magnification. (B) Representative 2D class averages for the non-crosslinked p97-ataxin3 
complex (left) and p97 alone (right). From the 20,256 particles selected, only ~1,300 particles 
were sorted into classes that show the additional blurred density corresponding to ataxin3. No 
side views of the p97 hexamer were observed in any samples, suggesting that the relatively flat, 








Appendix 2 Supplemental Figure S3. Comparison of non-crosslinked and crosslinked 
samples. (A) Negative-stained electron micrographs showing p97 alone, non-crosslinked p97-
ataxin3 complexes, and crosslinked complexes. Insets show a representative 2D class average 
from each experiment. Note the presence of numerous particles in the middle micrograph (black 
arrows), of a size significantly smaller than the expected dimensions for p97; these particles are 
absent in the other two micrographs. These particles may represent free ataxin3, implying that 
the complex has dissociated either during the SEC step or during grid preparation. The blurred 
density seen for the non-crosslinked complexes might therefore reflect partial dissociation, 
which is resolved by crosslinking. (B) Workflow for preparation of complexes for EM, along with 
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SEC chromatograms for p97 alone, ataxin3 alone, and the non-crosslinked, crosslinked and 
Nanogold-labelled complexes. The black arrows indicate the fractions used for negative-stain 
EM. As seen from the position of the peaks, the complex peak may overlap with the p97-alone 
peak. In the non-crosslinked experiment, the inability to resolve these peaks may have 
introduced free p97 in the fraction applied to the grids, which would also account for the 
relatively low fraction of particles containing the complex (~5% of the total particles). The 
crosslinking, affinity purification, and centrifugation steps aided in removal of unbound p97 and 
ataxin3 (note the disappearance of the ataxin3 alone peak in the chromatogram for the 
crosslinked complex). The p97-alone chromatogram shows a typical purification profile similar 
to others described previously, with irreversibly aggregated material in the void volume peak 
(54). Note that a different SEC column was used for the Nanogold-labelled material as compared 













Appendix 2 Supplemental Figure S4. SDS-PAGE gel of the crosslinked and non-
crosslinked EM complexes. The gel is stained with Coomassie Brilliant Blue. Lane 1 is the 
His6-ataxin3-p97 complex crosslinked with 0.05% glutaraldehyde and purified by immobilized 
metal-affinity chromatography. Lane 2 is the crosslinked sample from lane 1 after SEC. Lanes 3 
and 4 are the p97-ataxin3 complex without crosslinker before and after SEC respectively. In 
lanes 2 and 4, the tagged and untagged ataxin3 bands are not visible at the dilutions obtained 









Appendix 2 Supplemental Figure S5. p97 complexed with Nanogold-labeled ataxin3. (A) 
Raw images of p97 complexed with Nanogold-labelled ataxin3. One single gold particle, visible 














Appendix 2 Supplemental Figure S6. ATPase activities of wild-type and mutant p97. (A) 
ATPase activities of full-length wild-type p97 (untagged and tagged), four cofactor binding-cleft 
mutants, and three Walker mutants (all mutants are 1D4-tagged). The C-terminal 1D4 and His6 
tags do not affect ATP hydrolysis. G54W is not an identified MSP1 mutation and it is thus unclear 
why that mutant has elevated activity (n ≥ 3 for all measurements). (B) We noticed that the 
relative activities of Walker mutants vs. wild-type p97, as shown in panel (A), do not follow the 
same trend as seen in Briggs et al. (8); specifically, in our hands, the K524A mutants appear to 
possess higher activity than previously reported. However, the activities cannot be directly 
compared, since different assay conditions were used. The experiments in panel (A) rely upon a 
coupled assay linked to NADH consumption and were performed at room temperature; in 
contrast, the Briggs et al. experiments utilize a colorimetric Malachite Green assay, performed 
at 37°. Therefore, to determine whether these disparities in relative activities reflect differences 
in the assay conditions or genuine differences in the proteins, we measured the ATPase 
activities of our p97 proteins using a Malachite Green assay at 37 °C, as described in (8). We 
found that under these conditions, the activities of our different p97 variants follow a trend that 
is very similar to previously published results (52,209), demonstrating that the apparent disparity 
in activities results from different assay conditions, and not from different behavior on the part 















Appendix 2 Supplemental Figure S7. ATPase activities of full-length wild-type p97 and 
three MSP1 mutants. The mutants show increased activity as compared to the wild-type, 













Appendix 2 Supplemental Figure S8. ATPase activity in the presence and absence of DTT. 
ATPase activities of full-length wild-type p97 (WT), the R155C/N387C double mutant, and the 
L198W and A232E MSP1 mutant versions of the R155C/N387C double mutant, all measured in 
the presence and absence of DTT. Note that the disulfide-locked form (– DTT) of the 
R155C/N387C double mutant has very low activity, which is rescued in the presence of reducing 
agent (+ DTT). The L198W and A232E versions of the R155C/N387C double mutant show no 
difference in activity with and without DTT. This suggests that in the two mutants, Cys-155 and 
















Appendix 2 Supplemental Figure S9. Ataxin3ΔC binds a conformationally-locked form of 
p97, unlike full-length ataxin3. Ataxin3ΔC binds equally to the disulfide-locked form (– DTT) 
and reduced form (+ DTT) of the R155C/N387C p97 double mutant, unlike full-length ataxin3. 
Normalized equilibrium binding response for (A) ataxin3ΔC and (B) full-length ataxin3 binding 
to the R155C/N387C double mutant, in the presence and absence of 7 mM DTT (n ≥ 3 at each 

















Appendix 2 Supplemental Figure S10. Ataxin3 binds MSP1 versions of the R155C/N387C 
double mutant. Ataxin3 binds the MSP1 mutant versions of the R155C/N387C double mutant, 
both in the presence and absence of DTT. Normalized equilibrium binding response for ataxin3 
(n ≥ 3 at each concentration) binding to the (A) L198W and (B) A232E versions of the 














Appendix 2 Supplemental Figure S11. Elution profiles of full-length p97 from size-
exclusion chromatography. SEC elution profile of full-length p97 from the (A) Sephacryl S-300 
preparative column and (B) Yarra SEC-3000 column. The void peak in both contains aggregated 
material. A smaller peak is resolved in (B), eluting between the void and hexamer peaks, and 
most likely contains higher-order oligomers such as dodecamers and/or small aggregates. The 
















Appendix 2 Supplemental Figure S12. Global 1:1 kinetic analysis of full-length ataxin3 
binding to full-length p97. Representative SPR sensorgrams for the binding of full-length 
ataxin3 to full-length 1D4-tagged p97. Highest ataxin3 concentration = 10 µM; other 
concentrations obtained by successive 3-fold dilutions. The orange lines represent a global fit 
to a one-site kinetic model. Note that the fit deviates considerably from the sensorgrams, 
especially at the lower concentrations, and thus reliable kinetic rates cannot be derived. This 
could either be resolved by fitting to a more complex model or by accounting for surface-









Appendix 2 Supplemental Figure S13. Detecting the presence of mass-transport 
limitations in the p97-ataxin3 system. (A) Comparison of the association signals from 10 µM 
ataxin3 binding to different densities (50–350 RU) of the immobilized ligand p97-1D4. The 
responses are normalized to the density of p97-1D4 on each corresponding surface. 
Superimposable responses were obtained for surfaces with densities between 50–200 RU; 
ligand densities greater than 200 RU showed slower association, indicating the presence of 
mass-transport effects. (B) Data showing the association and dissociation between 10 µM 
ataxin3 analyte and p97-1D4 ligand, obtained under standard experimental conditions (blue 
line), and rebinding test conditions (dashed red line). Rebinding was tested by injecting excess 
untagged p97 during the dissociation phase (instead of the running buffer alone); the excess 
p97 serves as a competitor and binds the dissociated ataxin3, preventing its rebinding to the 
immobilized p97-1D4. Note the significantly faster dissociation under these conditions, 
indicating that analyte rebinding is occurring under the standard experimental conditions, 
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Appendix 3 Supplementary Table 1. Expression constructs and primers used to generate the 
ubiquitin proteins.  





























Appendix 3 Supplementary Table 2. Primers used for one-step site-directed mutagenesis of 












S236A 1: GGCACTAGCACGCCAAGAAATTGACATGGAAGATGAGGA 
AGCAG 
2: CTTGGCGTGCTAGTGCCAGAGCCCTCTGCAAATCCTCCTC 















Appendix 3 Supplemental Figure S1. The ubiquitin constructs alone do not contribute 
fluorescence. Representative plot showing the increase in fluorescence over time for ataxin3 
alone (black line), and the control reactions with Ub (grey dashes) and UbHis6 (grey line) in the 
absence of the DUB. The ubiquitin constructs do not produce any increase in fluorescence by 











Appendix 3 Supplemental Figure S2. The His6-tagged MBP control does not stimulate 
ataxin3 activity. Representative plot showing the increase in fluorescence over time for ataxin3 
in the presence of UbHis6 (black line), and His6-MBP (grey dashes) at the same concentration 
(75 µM). The His6-MBP control reaction does not show any increase in fluorescence, and thus, 
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